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Steady State and Theoretical investigations of Peptidylyglycine α-Amidating Monooxygenase
Edward W. Lowe, Jr.
ABSTRACT
Approximately 50% of all known peptide hormones are post-translationally modified at
their C-terminus. These peptide hormones are responsible for cellular functions critical to
survival. Peptidylglycine α-amidating monooxygenase (PAM) is a bi-functional enzyme which
catalyzes the conversion of peptide pro-hormones to peptide hormones. PAM is the only known
mammalian enzyme that catalyzes the necessary a-amidation to activate these peptide hormones.
PAM has previously been found to perform N-dealkylation, as well as O-dealkylation.
We report here that a novel chemistry for PAM, S-dealkylation, has now been shown. PAM was
able to catalyzes the hydroxylation and subsequent dealkylation for a series of substituted 2(phenylthio)acetic acid analogs, leaving a product containing a free thiol capable of coordinating
to copper(I).
A series of cinnamic acid derivatives have been investigated as turnover dependent
inactivators of PAM. It was shown that the inactivating compounds contained electron donating
substituents. All compounds bound competitively versus substrate, though no catalytic activity
was noted when tested as substrates. Although no Dkinact was observed when using perdeuterated
cinnamic acid, one cannot rule out hydrogen abstraction from the Cα as this step may not be rate
limiting for inactivation. This suggests that the activated oxygen species generated at CuM may
be sufficiently reactive to abstract a hydrogen from an alkene to generate a vinyl radical.
x

Substrate activation is believed to be facilitated by a Cu(II)-superoxo complex formed at
CuM. Hydrogen abstraction from the Cα is hypothesized to generate a radical, though this has
never been demonstrated spectrometrically. We report here further evidence for the generation
of a Cα radical by comparing log(Vmax/KO2) vs σ+ for a series of ring-substituted 4-phenyl-3butenoic acids.
Lastly, a computational study was carried out to probe for a possible binding pocket for
the reductant, ascorbate. Though crystal structures have argued that reduction of the enzymebound coppers is collisional, kinetic data for inhibitors competitive against ascorbate indicates
that a discrete binding pocket may exist. Our study suggests a specific site for binding and
provides free energy calculations in agreement with experimental values for binding constants

xi

Chapter One: Introduction

Peptide Hormones

Approximately 50% of all known mammalian peptide hormones are α-amidated. In
insects, over 90% of peptide hormones are α-amidated. The amino acid prohormone sequence of
these peptides contains a C-terminal glycine. The amidation of the carboxy-terminus is essential
for activation of these peptide hormones as the glycine-extended precursors are generally >1000fold less potent than the α-amidated peptides [1]. Some of these amidated hormones act as
neurotransmitters. Many α-amidated peptide hormones have been found to be over-expressed in
human disease states such as substance P in rheumatoid arthritis [2, 3], luteinizing hormonereleasing hormone and vasoactive intestinal peptide in cancer[4, 5], and corticotropin-releasing
factor in anxiety and depression[6]. The fact that the precursor sequences for these essential
amidated hormones all contained a C-terminal glycine suggested that the C-terminal amide
biosynthesis required the action of a specific enzyme to activate these peptide prohormones
through the functionalization of the glycine (Figure 1.1). In 1982, the enzyme responsible for the
conversion of glycine-extended peptides to the corresponding peptide-amide was discovered in
porcine pituitary[7].
PAM: The α-Amidating Enzyme
Peptidylglycine α-amidating monooxygenase (PAM) is a bifunctional coppermonooxygenase. PAM is found within neuronal and endocrine cells, neurosecretory vesicles,
and the highest concentrations are found in the atrium of the heart [8-11]. PAM is primarily
responsible in vivo for the activation of peptide hormones through the conversion of the glycineextension to the corresponding amide. PAM also plays a role in the biosynthesis of fatty acid
amides [12-15]. PAM is the only mammalian enzyme known to catalyze this amidation reaction.

1
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PAM (E.C. 1.14.17.3) consists of two hetero-domains which are peptidylglycine α-

hydroxylating monooxygenase (PHM) and peptidylglycine amidoglycolate lyase (PAL) (Figure
1.2). The PHM domain has been deeply studied primarily due to its similarity in both reaction
and structure to another copper-dependent monooxygenase, dopamine β-monooxygenase [16,
17]. Dopamine β-monooxygenase (DβM, E.C. 1.14.17.1) catalyzes the stereospecific conversion
of dopamine to norepinephrine (Figure 1.3) [16, 18]. This tetrameric protein exists in both
membrane and soluble forms within neurosecretory vesicles of the sympathetic nervous system
[19]. While dopamine is a neurotransmitter in the central nervous system, its functionalization to
norepinephrine by DβM allows for its functioning in the sympathetic nervous system which
consists of neuronal axons that interact with smooth muscle and the catecholamine secreting
cells within the adrenal medullae [20].
PHM and DβM
PHM and DβM are stru ctu rally similar. The en zymes share a 2 8 % id entity and 4 0 %
sequence similarity in the catalytic core [17, 21]. Both contain a large, solvent accessible active
site flanked by two non-coupled copper atoms [22-24]. PHM catalyzes the copper-, O2-, and
ascorbate-dependent hydroxylation of a glycyl Cα while DβM catalyzes the copper-, O2-, and
ascorbate-dependent hydroxylation of a benzylic carbon (Figure 1.4) [16, 22, 25-27]. While
PHM has been successfully crystallized, DβM has not [28]. The crystal structure of PHM
reveals it to be a prolate ellipsoid composed of two 9-stranded β-sandwich domains (Figure 1.5).
The domains are approximately of equivalent size and are held together by a 500 Å2 interface.
The active site is a large, solvent accessible cleft residing at the interdomain interface with two
bound coppers, one on each side of the cleft (Figure 1.6). Each domain is centered around their
respective copper atom. Each of the two coppers has a different ligand set. One copper center,
2
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CuM, has two histidine Nε ligands and a methionine sulfur ligand (H242, H244, M314). The

remaining copper center, CuH, has three histidine Nδ ligands (H107, H108, H172) (Figure 1.7).
This is also the case in DβM as one copper is coordinated to three histidines and the other to two
histidines and a methionine. The enzyme was co-crystallized with N-acetyl-3,5-diiodotyrosylthreonine, a poor substrate for PHM. The substrate appears to form a salt bridge between the
carboxy-terminus and the guanidino group of arginine 240 (Figure 1.8). This places the substrate
in close proximity to the CuM where O2 has been found to bind and where activation of O2 is
thought to occur. Hydrogen bonding between the glycyl amide-hydrogen and the side chain
oxygen of N316 also plays a role in the proper positioning of the substrate. Crystal structures for
oxidized, reduced, and pre-catalytic forms of PHM with substrate bound have been solved [2830]. The crystal structures are surprisingly identical with no differences seen between the
oxidized and reduced form and an rmsd value of 0.27 (Figure 1.9). This suggests that movement
or closure of the active site during catalysis does not occur. These structures also revealed that
the copper atoms are ~10.6 Å apart which is in good agreement with previous extended X-ray
absorption fine structure (EXAFS) data for DβM which suggested the copper atoms were more
than 4 Å apart [21, 28, 30-32]. These data along with electron paramagnetic resonance (EPR)
data suggests that PHM and DβM are non-coupled di-copper enzymes or ‘non-blue’/type-II
enzymes [22, 33, 34]. The geometries of the two copper sites were found to change upon
reduction. CuM is observed to have a square pyramidal geometry while in the oxidized form
while CuH is square planar. Upon reduction, CuM becomes tetrahedral and CuH becomes Tshaped. The bond length of CuM-SM314 has been shown to tighten in the reduced form compared
to oxidized enzyme according to EXAFS data suggesting that the oxidized form is more distorted

3
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tetrahedral than square planar [34]. EXAFS data also suggests that CuH is coordinated to only
two of the three histidine residues in the reduced form.
Both PHM and DβM catalyze very similar reactions.

The PHM reaction involves

hydrogen abstraction from a substrate by some activated Cu-O species followed by the
subsequent stereospecific hydroxylation of the pro-S g yl cyl Cα.

The DΒM reaction also

involves the abstraction of hydrogen, but does so from a benzylic carbon followed by pro-R
hydroxylation. In both cases, the mechanism is believed to involve electron transfer from CuH
to CuM.
PHM/DβM Postulated Mechanisms
The first step involved for catalysis is the irreversible reduction of both enzyme bound
coppers by ascorbate allowing di-oxygen and substrate to bind to the reduced enzyme [16, 21,
35, 36]. This reduction is a “ping-pong” mechanism. Burst phase kinetic experiments with
DβM have shown that pre-reduced enzyme is capable of hydroxylating substrate with the
amplitude of the pre-steady state burst being equivalent to the concentration of enzyme [37-39].
This indicates that the chemical step is much faster than product release and also allowed for reoxidation with product release to be observed. A temperature dependence on primary and
secondary intrinsic isotope effects for Cα-H cleavage has also been observed for PAM. This
non-classical behavior suggests that quantum tunneling is involved in hydrogen transfer [40].
18

O kinetic isotope effects have been used to probe the nature of the activated Cu/O

species responsible for hydrogen abstraction.

These studies on both PHM and DβM only

provide information up to and including the O-O cleavage step due to the quantum mechanical
nature of hydrogen transfer [41]. When coupled with substrate deuterium isotope effects, the
4
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data for PHM and DβM indicates that C-H bond cleavage occurs prior to that of O-O necessary
for hydroxylation [42-45]. This suggests that a Cu(II)-hydroperoxo is being formed during
hydrogen abstraction but lends no evidence as to what the hydroxylating species may be. Rapid
freeze quench EPR data also suggests that a copper-superoxo species is formed, as O-O and C-H
cleavage are tightly coupled [46]. The data suggest that the substrate intermediate resulting from
Cu(II)-superoxo abstraction of hydrogen would be a radical intermediate. Evidence for a radical
mechanism has been found in DβM [47-49]. This evidence has been applied towards the PHM
mechanism though it has not been proven directly for PHM.
Several competing reaction mechanisms have been proposed for PHM and DβM. Two of
these competing mechanisms both support a copper-superoxo nucleophile for hydrogen
abstraction. While the nature of the hydrogen acceptor is in agreement, the initial geometry of
the di-oxygen species to copper is in question. Spectroscopic data has indicated a side-on/η2
species but was based on model studies and not PHM or DβM [50, 51]. When compared to the
end-on/η1 species, the side-on Cu(II)-superoxo was determined computationally to be more
thermodynamically favorable [52, 53]. However, crystallographic evidence of a pre-catalytic
state of PHM with good resolution (1.85 Å) has found the end-on/η1 species present (Figure
1.10) [28]. Upon forming either disputed Cu-superoxo species, both mechanisms proceed to
abstract hydrogen to form a Cu(II)-hydroperoxo species.

This hydroperoxo species is

coordinated to copper in an end-on/η1 geometry. The competing mechanisms again diverge as
the side-on/η2 mechanism predicts direct hydroxylation of the resulting substrate radical
followed by radical recombination. The net effect is reduction of the copper(II)-hydroperoxo
species and release of the hydroxylated product. Electron transfer would then occur from CuH to
complete the reaction.
5
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On the other hand, the end-on/η1 mechanism postulates that the Cu(II)-hydroperoxo
species is reduced by an electron transfer event prior to hydroxylation of the substrate radical.

This electron provided by the CuH site allows for homolysis of the Cu(II)-O-OH yielding a
Cu(II)—O• species. This newly formed Cu/O• would then recombine with the substrate radical
intermediate resulting in a covalent, inner-sphere alcohol intermediate. Product release then
occurs via hydrolysis of this intermediate. The proposed mechanisms are compared in Figure
1.11.
While experimentalists agree that the hydrogen abstracting species is, indeed, a coppersuperoxo, several theoreticians have proposed that a different activated Cu/O species is
responsible for this chemistry. Using a series of molecular dynamics (MD) and mixed quantum
mechanics molecular mechanics (QM/MM) calculations, two separate mechanisms have been
proposed. The species proposed as responsible for hydrogen abstraction is a reduced copperoxo. This suggests that di-oxygen reduction and substrate activation are uncoupled which is in
direct contrast to experimental data. QM/MM simulations suggest that Cu(III)-oxide/Cu(II)-oxyl
species are thermodynamically favored over the superoxo/hydroperoxo species proposed by
experimentalists [54-56]. These theoretical mechanisms suggest that electron transfer precedes
hydrogen abstraction allowing Cu(II)-superoxo to acquire two protons from solvent. Water is
then released from the Cu(II)-O-OH2 species leaving either a Cu(II)-oxyl quartet or a Cu(II)-oxyl
triplet species to abstract hydrogen from the substrate. The quartet is proposed to concertedly
abstract the substrate hydrogen and hydroxylate the radical intermediate with a spin inversion to
the doublet ground state occurring upon substrate oxidation[54]. This suggests that substrate
oxidation and product release happen simultaneously. A water molecule would then bind to the
remaining Cu(II) to restore proper geometry in the oxidized state. The triplet Cu(II)-oxyl is
6
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believed to undergo a spin inversion event to the singlet ground state upon substrate C-H
oxidation driving concerted product release [55, 56]. These two theoretical mechanisms are
compared in Figure 1.12.
Peptidylglycine Amidoglycolate Lyase
The lyase domain in PAM responsible for carbinolamide dealkylation of the αhydroxyglycine PHM product resulting in the corresponding amide and glyoxylate is the PAL
domain. This 33 kDa monomer is zinc-, calcium-, and iron-dependent and bound to the Cterminus of the PHM domain.

Although the complete PAL mechanism is unknown, it is

believed to proceed through a zinc-hydrolase-type reaction [57]. The iron is involved in a
tyrosine bridged Zn(II)-Fe(III) complex.

Mutation of this tyrosine (Y564) results in PAL

inactivation and the inability to bind iron. No substrate channeling between PHM and PAL has
been observed. While the inclusion of the PAL domain in PAM provides the key difference
between PAM and DβM, DβM has also been noted to catalyze several N-dealkylation reactions
solely through hydroxylation like that of benzylic N-substituted analogues [58]. PAM and DβM
have also both demonstrated sulfoxidation while PAM has demonstrated O-dealkylation [59].
Introduction to Chapters
PAM has previously been found to perform N-dealkylation, as well as Odealkylation. We report here that a novel chemistry for PAM, S-dealkylation, has now been
shown. PAM was able to catalyzes the hydroxylation and subsequent dealkylation for a series of
substituted 2-(phenylthio)acetic acid analogs, leaving a product containing a free thiol capable of
coordinating to copper(I).

7

Chapter One: Introduction

A series of cinnamic acid derivatives have been investigated as turnover dependent

inactivators of PAM. It was shown that the inactivating compounds contained electron donating
substituents. All compounds bound competitively versus substrate, though no catalytic activity
was noted when tested as substrates. Although no Dkinact was observed when using perdeuterated
cinnamic acid, one cannot rule out hydrogen abstraction from the Cα as this step may not be rate
limiting for inactivation. This suggests that the activated oxygen species generated at CuM may
be sufficiently reactive to abstract a hydrogen from an alkene to generate a vinyl radical.
Substrate activation is believed to be facilitated by a Cu(II)-superoxo complex formed at
CuM. Hydrogen abstraction from the Cα is hypothesized to generate a radical, though this has
never been demonstrated spectrometrically. We report here further evidence for the generation
of a Cα radical by comparing log(Vmax/KO2) vs σ+ for a series of ring-substituted 4-phenyl-3butenoic acids.
Lastly, a computational study was carried out to probe for a possible binding pocket for
the reductant, ascorbate. Though crystal structures have argued that reduction of the enzymebound coppers is collisional, kinetic data for inhibitors competitive against ascorbate indicates
that a discrete binding pocket may exist. Our study suggests a specific site for binding and
provides free energy calculations in agreement with experimental values for binding constants.
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Figure 1.1. Pro-substance P converted to the bioactive substance P through some amidation
mechanism.
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Figure 1.5. PHM crystal structure (reduced) in licorice representation. Note, carbons are
teal, oxygens are red, nitrogens are blue, sulfurs are yellow, and hydrogens are not shown
for clarity.
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Figure 1.6. PHM crystal structure shown with bound coppers flanking the active site.
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Figure 1.7. The two copper centers in the PHM crystal structure coordinated to their
respective 3-ligand system. Note, only the side chains of the residues are shown methylcapped.
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Figure 1.8. PHM crystal structure with IYT forming a salt-bridge with R240.
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Figure 1.9. PHM crystal structures of reduced (red) and oxidized (blue) forms aligned show
very little differences in structure versus redox state (Rmsd = 0.27 Å).
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Figure 1.10. The pre-catalytic PHM crystal structure with oxygen bound to CuM in end-on
fashion.
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Introduction

Peptidylglycine α-amidating monooxygenase (PAM) catalyzes the oxidative cleavage of
C-terminal glycine-extended peptide hormones[1], fatty acid precursors [2-5], and bile acids [6]
to the corresponding amides and glyoxylate. This two-step amidation proceeds via a copper-,
O2-, and ascorbate-dependent glycyl Cα hydroxylation followed by a zinc-, iron-, and calciumdependent dealkylation of the carbinolamide intermediate (Figure 2.1). This bifunctional nature
is

attributable

to

the

peptidylglycine

α-hydroxylating

monooxygenase

(PHM)

and

peptidylglycine amidoglycolate lyase (PAL) domains, respectively [7, 8]. This α-amide moiety
is a requisite for most active peptide hormones, with the amidated derivatives generally
displaying >1000-fold more potency than the glycine-extended precursor[1].

PAM is

responsible for the activation of many important neuropeptides such as substance P and oxytocin
[9-11]. While this is the primary in vivo function of PAM, alternate catalytic functions have
been reported including sulfoxidation, and O-dealkylation [12].
PAM/PHM is a potential therapeutic target because of the roles played by α-amidated
peptides in disease states. Some examples of α-amidated peptides implicated in disease are
luteinizing hormone-releasing hormone (cancer), vasoactive intestinal peptide (cancer),
substance P (rheumatoid arthritis), and corticotropin-releasing factor (anxiety and depression).
Because prevention of amidation often reduces the efficacy of peptide hormones by ~3 orders of
magnitude, broad inhibition of PAM may be overly toxic by blocking the conversion of essential
mammalian α-amidated peptides.
Toxicity may, however, prove useful in the possible development of insecticides. Insects
possess separate PHM and PAL monomers and lack the bi-functional PAM enzyme [13, 14].
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Elimination of expression in Drosophila melanogaster has been demonstrated to be lethal [14].
Because the mammalian PHM sequence and Drosophila PHM sequence share 41% identity and
52% similarity, sufficient differences may exist to target only the insect enzyme.

Several (2-phenylthio)acetic acid (PTAA) derivatives were investigated as inhibitors of
PAM activity. PTAA displays characteristics of a turnover-dependent inactivator of PAM. We
now report that PAM can catalyze S-dealkylation. This S-dealkylation leaves a free thiol capable
of in situ coordination of the active site CuM leading to reversible inactivation of PAM. This
discovery may give a new direction for the design of PAM inhibitors. The S-Cα moiety allows
for the design of PAM specific pro-drugs that rely on PAM turnover for drug activity.
MATERIALS AND METHODS
Materials.
[(1-H-indole-2-ylcarbonyl)thiol]acetic acid and 2-(phenylthio)acetic acid were purchased
from Sigma, 2-(4-chlorophenylthio)acetic acid was purchased from Pfaltz & Bauer, Inc., 2-(4methylphenylthio)acetic acid was purchased from Aldrich Chem. Co., 2-(benzoylthio)acetic
acid, 2-(2-nitrophenylthio)acetic acid, N-benzoyl-D-alanylthioglycolic acid were purchased from
Eburon Organics N.V., and bovine catalase was from Worthington. Recombinant rat PAM was a
gift from Unigene Laboratories, Inc. All other reagents were of the highest quality from
commercial suppliers.
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Synthesis of α-di-deutero-2-(phenylthio)acetic acid

Thiophenol (6.1 mL, 60 mmol) in aqueous sodium hydroxide (20 mL 6M) was reacted
with (α-D,D) bromoacetic acid (12.5 gm, 90 mmol) for 2 hr at 50 oC. The reaction was then
acidified with dilute HCl(aq), precipitate collected, and re-crystallized twice in hot ethanol.
Determination of KM,app and VMAX,app values for 2-(phenylthio)acetic acid (α-H,H and α-D,D), 2(4-methylphenylthio)acetic

acid,

2-(4-chlorophenylthio)acetic

acid,

and

1-H-indole-2-

ylcarbonyl)thiol]acetic acid.
Reactions at 37.0 ± 0.1 °C were initiated by the addition of PAM (20-50 µg) into 2.0 ml
of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10
µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 0.1 – 6.0 mM of the
oxidizable substrate. Initial rates were measured by following the PAM-dependent consumption
of O2 using a Yellow Springs Instrument Model 5300 oxygen monitor interfaced with a personal
computer using a Dataq Instruments analogue/digital converter (model DI-158UP). VMAX,app
values were normalized to controls performed at 11.0 mM N-acetylglycine.
Inhibition of O2 consumption from N-acetylglycine by 2-(phenylthio)acetic acid

Reactions

at

37.0 ± 0.1 °C were initiated by the addition of PAM (35 µg) into 2.0 ml of 100 mM MES/NaOH
pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase,
1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, 8 mM N-acetylglycine, and 0-5 mM 2(phenylthio)acetic acid.

Initial rates were measured by following the PAM-dependent

consumption of O2 using a Yellow Springs Instrument Model 5300 oxygen monitor.
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Glyoxylate production from 2-(phenylthio)acetic acid derivative substrates

To first determine if the PHM-hydroxylated 2-(phenylthio)acetic acid was a substrate for
PAL, 20 µg of PAM was added to a 2.0 mL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0%
(v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/mL catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium
ascorbate, and 10 mM 2-(phenylthio)acetic acid. After incubation for 2 hr. at 37°C, the reaction
was terminated by the addition 500 µL of 6% (v/v) TFA and duplicate 500 µL aliquots were
removed for glyoxylate analysis.
Initial rates of glyoxylate formation from 2-(phenylthio)acetic acid were determined by
adding 20 µg of PAM to a 3.0 mL solution containing 100 mM MES/NaOH pH 6.0, 30 mM
NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/mL catalase, 1.0 µM Cu(NO3)2, 5
mM sodium ascorbate, and 10 mM 2-(phenylthio)acetic acid. At 30 min. intervals for 150 min., a
500 µL aliquot was removed, added to a vial containing 100 µL of 6% (v/v) TFA to terminate
the reaction, and the concentration of glyoxylate formed measured in the acidified samples.
Initial rates of glyoxylate formation from α-hydroxyhippurate, a known PAL substrate, as
a function of the 2-(phenylthio)acetic acid concentration were determined by adding 20 µg of
PAM to a 1.5 mL solution containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v)
ethanol, 0.001% (v/v) Trition X-100, 10.0 mM α-hydroxyhippurate, and 0-10.0 mM 2(phenylthio)acetic acid. At 10 min. intervals from 10 to 60 min., a 100 µL aliquot was removed,
added to a vial containing 20 µL of 6% (v/v) TFA to terminate the reaction, and the
concentration of glyoxylate formed measured in the acidified samples.
Glyoxylate was determined by the spectrophotometric method of Christman et al. [15] as
modified by Katopodis and May [12]. Standard curves of [glyoxylate] vs. A520 were constructed
in the appropriate buffers using a glyoxylate solution that had been standardized by measuring
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3

-1

-1

the glyoxylate-dependent oxidation of NADH (∆ε340 = 6.22 x 10 M cm ) as catalyzed by
lactate dehydrogenase.
RP-HPLC separation of 2-(phenylthio)acetic acid and thiophenol.

HPLC analyses were performed using a Hewlett-Packard 1100 liquid chromatography
system equipped with an auto-sampler and quaternary pump system. Aliquots (10 µL) of the
reaction mixture were analyzed using a Phenomenex Luna 5µ C18 (250 x 4.60 mm) column. The
mobile phase was a linear 70-100% gradient of 50 mM sodium acetate pH 6/acetonitrile (85/15)
in acetonitrile. Analytes were detected at 254 nm.
Analysis of steady-state kinetic data
Steady-state kinetic parameters were obtained by Kaleidagraph fit of the initial velocity
(v) vs. substrate concentration, ([S]), data to

(1)

Where KM,app is the apparent Michaelis constant for the oxidizable substrate at fixed [ascorbate]
and [O2] concentrations and VMAX,app is the apparent maximum initial velocity at saturating [S].
Initial rate studies that resulted in competitive inhibition were also analyzed by Kaleidagraph fit
of v vs. [S] as a function of inhibitor concentration to equation 2.

(2)
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The crystal structure for reduced peptidylglycine α-hydroxylating monooxygenase
(PHM) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW) [16]. All
co-crystallized species determined to be redundant for ligand binding were removed (nickel,
water, glycerol, and substrate). Formal charges for enzyme-bound copper ions and bond orders
were corrected, and hydrogens were added using Maestro (www.schrodinger.com). Further
receptor refinements were carried out utilizing ProteinPrep from within Maestro. Glide and Qsite from the FirstDiscovery 3.0 suite (www.schrodinger.com) were used for quantum polarized
ligand docking (qpld) to generate highly accurate ligand binding modes [17, 18].
Computational Chemistry
The top pose from the in silico docking studies of thiophenolate was used as input for the
geometry optimization of the L3Cu-thiophenolate system. The CuM ligand set, H242, H244, and
M314, were truncated to methyl-capped side chains to lessen the computational expense of
geometry optimizing the system. Three systems were thus created. System 1 included the
previously mentioned methyl-capped side chains, Cu1+, and a single water molecule coordinated
to the copper (Figure 2.2).

System 2 included, once again, the L3Cu1+ system, but the

coordinated water was replaced by the qpld docked thiophenolate (Figure 2.3). The final system,
System 3, contained only the three-residue CuM coordination site along with Cu1+ (Figure 2.4).
The geometries of these two systems were optimized using density functional theory with
B3LYP hybrid exchange-correlation and the LanL2DZ+ECP basis set [19-21].
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RESULTS AND DISCUSSION
2-(phenylthio)acetic acid as a PAM substrate
The addition of PAM to solutions containing p-Cl-PTAA resulted in the consumption of
O2 (Figure 2.5). The dependence of the initial rate of O2 consumption on the initial concentration
of PTAA, at a fixed concentration of reductant and O2, is described by equation 1 yielding the
steady-state kinetic values for KM,app, VMAX,app, and (V/K)app included in Table 2.1. Investigation
of α-d,d-PTAA gave a D(V/K)app isotope effect of 1.9 giving further proof that the Cα-H bond
cleavage was occuring. Incubation of 10 µg/mL PAM with 10 mM PTAA for 1 hr at 37 oC
yielded 96 µM glyoxylate verifying that PTAA is indeed a substrate and alluding to the
inactivating species, thiophenol (Figure 2.6).
2-(phenylthio)acetic acid derivatives as PAM substrates and inhibitors
The pattern of O2 consumption observed for all PTAA-related substrates appeared
characteristic of that of a mechanism-based inhibitor indicating turnover followed by enzyme
inactivation. Because this inactivation was slow, analyses of initial rates in obtaining the steadystate kinetic parameters is valid.

Glyoxylate was also produced in all instances.

Those

compounds in which glyoxylate was not produced, however, neither consumed O2 nor
inactivated PAM. The derivatives which did not consume O2 when tested as substrates did
inhibit O2 consumption from N-acetylglycine (Figure 2.7) yielding the steady-state kinetic values
as described by equation 2 (Table 2.2). LC/MS of trypsin-digested PAM after incubation with
PTAA showed no labeling (data not shown) suggesting that the enzyme was not being covalently
modified as is typical of a mechanism-based inhibitor. LC/MS analysis did, however, indicate
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that thiophenol was being produced. An HPLC separation was then developed and thiophenol
was successfully found in the reaction mixture (Figure 2.8)
Product-mediated reversible inactivation
Thiophenol is a known Cu1+ chelator and interacts more weakly with Cu2+. It was
hypothesized that the thiophenol product either coordinate to active site copper, forming an E2Cu(II)/(I)·inhibitor complex, or removes the active site copper, forming a copper-free-E and
separate Cu(II)/(I)·inhibitor complexes. The copper free form of PAM is inactive [22, 23]. This
type of thiol-mediated inhibition is well-documented in both PAM and related enzyme dopamine
β-monooxygenase (DβM), both copper-dependent monooxygenases [24-27]. The inhibition of
PAM by homocysteine-extended peptides [28] and by captopril [29] has been attributed to
sulfur-copper interactions.

The inhibition of DβM by captopril, and glutathione has been

attributed to in situ chelation of the enzyme-bound coppers [30, 31]. If in situ chelation were
occurring, out-competing the S-Cu interaction leaving the enzyme-bound copper free to once
again support catalysis should be possible. Thus, a reaction was initiated with 20 µg of PAM
under the previously mentioned condition for monitoring O2 consumption and 5 mM 2-(4chlorophenylthio)acetic acid. Upon observing the inactivation of PAM, with the rate of O2
consumption matching that of the background prior to initiating the reaction with enzyme, the
reaction was spiked with HgCl2 to a final Hg2+ concentration of 5 µM. This caused a resumption
of O2 consumption of 2 µM, leading to the supposition that the stronger Hg-S interaction was
relieving the enzyme-bound copper of the proposed chelating species, thiophenol (Figure 2.9).
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Modeling of PTAA, analogs, and thiophenol in the PHM active site

The X-ray structures of oxidized and reduced PHM, the subunit responsible for
catalyzing the copper-dependent glycyl Cα hydroxylation, reveal that the enzyme-bound coppers
are ~11Å apart flanking a solvent-accessible active site cleft [16, 24]. CuH and CuM, named for
their respective ligands of three histidines (CuH), and two histidines and a methionine (CuM),
have different roles in catalysis as CuH is involved in electron transfer while CuM is the site of O2
activation and substrate hydroxylation. Utilizing the crystal structure of reduced PHM in a precatalytic state with O2 coordinated to CuM and a substrate analog in the active site (Figure 2.10),
we were afforded an excellent opportunity to model the sulfur-containing compounds and the
proposed product responsible for in situ chelation, thiophenol.
The reduced PHM crystal structure, 1SDW [16], was chosen for the docking studies. All
ligands were docked along with the proposed thiophenol product and the thiophenolate species
(C6H5S-), L and L- respectively. This thiolate species should account for ~20% of the product
under reaction conditions, pH 6.0. All of the analogs bound similarly to the reduced PHM
crystal structure, displaying a salt bridge of the carboxy terminus to the guanidine group of R240
similar to that of the natural glycine-extended substrates of PHM [24]. The greatest dissimilarity
in binding modes with that of the biological substrate is the absence of the glycyl amide
hydrogen bonding to the oxygen of N316 [24]. This interaction plays a large role in proper
positioning of the Cα-H for H abstraction (Figure 2.11).
Coordination of CuM by thiophenol
The binding mode from the qpld docking of thiophenolate was used as the starting
structure for the geometry optimization as indicated in the Materials and Methods section. The
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optimized geometries for the coordination of Cu1+ to the three residue coordination site in the

CuM domain were compared between the L3Cu1+-H2O system, the L3Cu1+ system, and the
L3Cu1+-thiophenolate system to investigate coordination stability and to determine whether the
coordination of the thiophenolate would disrupt the L3Cu1+ stability. The L3Cu1+ uncoordinated
system is as expected with coordination distances of 2.01, 1.98, and 2.43 Å to NH242,NH244, and
SM314 respectively (Figure 2.12).

The L3Cu1+-H2O geometry optimized system displaced a

tetrahedral geometry with coordination distances of 2.05, 2.01, 2.52, and 2.19 Å for NH242, NH244,
SM314, and H2O respectively (Figure 2.13).

This geometry is in good agreement with

experimental values for this coordination state in the CuM domain. The geometry optimization
for the final system revealed something unexpected. The thiophenolate anion disrupted the
geometry of the CuM and changed the coordination number of the system. The geometry shifts
from the typical slightly distorted tetrahedral from the water coordinated system to a trigonal
pyramidal 3-coordinate system with the SM314 4.75 Å away from CuM (Figure 2.14). The other
coordination distances are 2.13, 2.08, and 2.38 for NH242, NH244, and S-thiophenolate
respectively. This change in coordination number and geometry would greatly reduce the chance
of oxygen activation.
Conclusion
In conclusion, we have shown that PAM can catalyze the dealkylation of the R-S-Cα
moiety leaving a free thiol/thiolate capable of in situ coordination to enzyme-bound copper.
Recent work by the Merkler group has demonstrated that the inclusion of a sulfur atom in small
molecule inhibitors of PAM increases binding affinity regardless of oxidation state (in press).
The present work suggests that a pro-drug could be developed allowing PAM to catalyze the
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production of the free thiol thus greatly reducing the possibility for unintentional free thiol
interactions with other metallo-enzyme prior to contact with PAM.
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Figure 2.1. The reactions catalyzed by PHM and PAL. Bifunctional PAM is composed of
the two monofunctional enzymes. The possible role of Fe(III) in PAL catalysis is unclear.
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Figure 2.2. The CuM domain with the L3 side chains methyl-capped and a single water
molecule coordinated to Cu1+. Note, the carbons are displayed in teal, the nitrogens in
blue, the hydrogens in white, the oxygen in red, the sulfur in yellow, and the copper in
orange.
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Figure 2.3. The CuM domain with the L3 side chains methyl-capped and thiophenolate
coordinated to Cu1+. Note, the carbons are displayed in teal, the nitrogens in blue, the
hydrogens in white, the oxygen in red, the sulfur in yellow, and the copper in orange.
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Figure 2.4. The CuM domain with the L3 side chains methyl-capped and coordinated to
Cu1+. Note, the carbons are displayed in teal, the nitrogens in blue, the hydrogens in white,
the oxygen in red, the sulfur in yellow, and the copper in orange.
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Figure 2.5. The PAM-Dependent Consumption of O2 in the Presence of 2-(4chlorophenylthio)acetic acid. O2 consumption at 37°C was initiated by the addition of 20 μg
of PAM (A) to a 2.0 mL solution containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl,
1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 μg/mL catalase, 5.0 mM sodium
ascorbate, and 5 mM 2-(4-chlorophenylthio)acetic acid. O2 consumption was measured as
described in the materials and methods section. Note that the background rate has been
removed for clarity.
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Figure 2.6. Proposed 2-(phenylthio)acetic acid cleavage by PAM mechanism. Cα
hydroxylation (PHM) and subsequent S-Cα cleavage (PAL) produce thiophenol and
glyoxylate. Thiophenolate is a known Cu1+ coordinator.
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Figure 2.7. Inhibition of PAM by 2-(benzoylthio)acetic acid. Initial rates were determined
at 37 °C as described in the Materials and Methods section. The points are the
experimentally determined initial rates and the curve was drawn using the constants
obtained by computer fit to eq. 2. The error bars represent the standard deviation of
duplicate measurements of the initial rates.
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Figure 2.8. RP-HPLC analysis of PAM reaction containing PTAA as the substrate. The
mobile phase was a linear 70-100% gradient of 50 mM sodium acetate pH 6/acetonitrile
(85/15) in acetonitrile. The chromatograms shown are a thiophenol standard, a 2(phenylthio)acetic acid standard, and a reaction mixture after treatment with PAM,
respectively. Analytes were detected at 254 nm.
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Figure 2.9. Effects of mercury competition with thiol for copper on O2 consumption. The
reaction was prepared as indicated in the Materials and Methods section for monitoring
oxygen consumption. Upon initiation of the reaction with the addition of PAM (A), the
reaction went to completion which is indicated by the slope of oxygen consumption
matching that of the background rate prior to the addition of enzyme. The sample was
then spiked with HgCl2 to a final concentration of 5 µM (B). Oxygen consumption then
resumed until 1.2 µM of additional oxygen had been consumed. Note that the background
rate has been removed for clarity.
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Figure 2.10. PHM crystal structure. The 1SDW PHM crystal structure with the secondary
structure rendered as a ribbon. The copper is depicted in orange, the bound molecular
oxygen in red, and the substrate IYT rendered in tube format colored by atom
(red=oxygen, green=iodine, teal=carbon, blue=nitrogen).
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Figure 2.11. PTAA and N-benzylglycine docked into the PHM crystal structure. (A) PTAA
was docked into the PHM crystal structure (1SDW). The carboxylate forms a salt bridge
with the R240 guanidino as expected. However, the absence of an amide hydrogen
available for hydrogen bonding to the N316 oxygen allows for a great deal of movement
and prevents proper positioning of the Cα-H for abstraction by an activated-oxygen
species. (B) N-benzylglycine docked for comparison to illustrate proper hydrogen bonding
and positioning. Non-amide hydrogens were omitted for clarity.
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Figure 2.12. L3Cu1+ geometry optimized using the LanL2dz+ECP basis set.
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Figure 2.13. L3Cu1+-H2O system geometry optimized with the LanL2dz+ECP basis set.
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Figure 2.14. L3Cu1+-thiophenolate system geometry optimized with the LanL2dz+ECP
basis set.
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TABLES

Table 2.1. Steady-state kinetic constants for 2-(phenylthio)acetic acid and analogs

Name

Structure

[(1-H-Indol-2-

KM,app

Vmax,app

(VMAX/KM)app

(mM)

(s-1)

(mM-1 s-1)

2.3 ± 0.6

0.4 ± 0.01

0.17 ± 0.05

0.95 ± 0.13

1.5 ± 0.2

1.6 ± 0.3

3.1 ± 0.6

2.6 ± 0.2

0.84 ± 0.17

0.53 ± 0.11

1.8 ± 0.1

3.4 ± 0.7

4.2 ± 0.2

2.3 ± 0.4

0.55 ± 0.10

O
H
N

ylcarbonyl)thio]acetic acid

S

2-(phenylthio)acetic acid

COOH

S

COOH

S

COOH

α-D,D-2-(phenylthio)acetic
acid

D

D

2-(4-chlorophenylthio)acetic
S

COOH

acid
Cl

2-(4-methylphenylthio)acetic
acid

S

COOH
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Table 2.2. PAM Inhibitors.
Name

Structure

Kis,APP
(mM)

2-(benzoylthio)acetic

O

COOH

S

acid

1.9 ± 0.1
2-(2-

NO2
S

COOH

nitropheylthio)acetic
0.14 ± 0.02

acid
N-benzoyl-Dalanylthioglycolic acid

HOOC

S

H
N
O

0.89 ± 0.01

O
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Introduction

Peptidylglycine α-hydroxylating monooxygenase (PHM) is a copper-, oxygen- and
ascorbate-dependent enzyme responsible for activating glycine-extended peptide prohormones
through an oxidative cleavage yielding the corresponding peptide amide [1-6]. This reaction
proceeds through the abstraction of hydrogen from the glycyl Cα followed by hydroxylation of
said Cα and finally cleavage of the amide-Cα bond resulting in glyoxyate and the peptide amide.
This bifunctional enzyme consists of the peptidylglycine α-hydroxylating monooxygenase
(PHM) and the zinc-, calcium-, and iron-dependent peptidylglycine amidoglycolate lyase (PAL)
domains, responsible for the hydrogen abstraction and hydroxylation, and the hydrolysis of the
amide-Cα bond, respectively (Figure 3.1) [7, 8]. PHM and its sister enzy me, d op amin e βmonooxygenase, have been studied extensively and are mechanistically similar[9]. The products
of these reactions are essential signaling molecules which are stored in secretory granules and
used for intercellular communication.
PAM activates several inflammatory hormones such as substance P. Previous studies
have targeted PAM using mechanism-based inactivators to inhibit carrageenan-induced edema as
well as all three phases of adjuvant-induced polyarthritis in rats [10]. Substance P is also found
in the spinal fluid of fibromyalgia patients, making PAM a possible drug target for such
inflammatory diseases. Genetically engineered mice and Drosophila lacking a functioning PHM
gene generally die as embryos [11-13]. Thus, simply targeting PAM or PHM activity would be
lethal. However, with advances in tissue-specific targeted drug delivery, this will become less of
an obstacle.

58

Chapter Three: Cinnamic Acid Derivatives as Inactivators of PAM
Cinnamic acid and its derivatives are found in fruits, vegetables, and flowers. Cinnamic

acid is an intermediate in the shikimate pathway, the pathway which links carbohydrate
metabolism to the biosynthesis of aromatic compounds in plants. Recent studies on the utility of
cinnamic acid derivatives as insulin releasing agents have proven certain ring-substituted
cinnamic acids very effective in lowering plasma glucose levels [14, 15]. It has been suggested
that cinnamic acid derivatives may be effective as treatment of diabetes mellitus for the
regulation of blood glucose levels through the stimulation of insulin secretion [14].
Here we report on the investigation of several inactivators of PAM related to cinnamic
acid.

These compounds, whose derivatives are used as food and fragrance additives, are

structurally similar to a known suicide substrate, 4-phenyl-3-butenoic acid[16].

Our results

demonstrate that while the inactivation is turnover-dependent, the inactivator does not undergo
any detectible chemistry as is typical of a suicide substrate. This finding merits further study
into the effects of cinnamic acid inactivation of PAM in vivo as a potential drawback of using
these molecules as diabetes therapeutics.
Materials and Methods
Materials
Cinnamic acid, 2-trifluorocinnamic acid, 3-(3-pyridyl)acrylic acid, phenylpropiolic acid,
3,4-methylenedioxycinnamic acid, N,N-dimethylaminocinnamic acid, maleamic acid, Nphenylmaleamic acid, Urocanic acid, 4-aminocinnamic acid, and perdeuterated cinnamic acid
were from Sigma. Bovine catalase was from Worthington and 4-anilino-4-oxobut-2-enoic acid
was from Enamine. Recombinant rat PAM was a gift from Unigene Laboratories, Inc. All other
reagents were of the highest quality commercially available.
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Synthesis

Dansyl-4-aminocinnamic acid
A solution of dansyl-chloride (400 mg, 1.5 mmol) in a minimal dry pyridine (~2 mL)
was added dropwise to a N2-purged solution of 4-aminocinnamic acid (500 mg, 3.1 mmol) in 50
mL of dry pyridine at 60 °C.

After 24 hours, the reaction was diluted then extracted with Et2O

(100 mL x 3), yielding a yellow oil. Crystallization of the final dansyl-4-aminocinnamic acid
was done with methanol/ddH 2O (285 mg, 48%).
3-phenyloxirane-2-carboxylic acid
Cinnamic acid (5 g, 34 mmol) dissolved in a 30 mM NaOH(aq) (~100 mL) was combined
with an oxone (30 g, 98 mmol) solution in H2O (100 mL). A constant pH of six was maintained
over six hours through the addition of NaOH then stirred for an additional 16 hours. Acid
extraction (pH 1) of the reaction was performed with Et2O (500 mL) by vigorously stirring the
bi-phasic solution for ~2 hours. The organic layer was then separated and removed under
reduced pressure. The resulting residue was crystallized with ethanol/H2O (1.6 gm, 29%).
In silico ligand docking
The crystal structure for reduced peptidylglycine α-hydroxylating monooxygenase
(PHM) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW) [17]. All
co-crystallized species determined to be redundant for ligand binding were removed (nickel,
water, glycerol, and substrate). Formal charges for enzyme-bound copper ions and bond orders
were corrected, and hydrogens were added using Maestro (www.schrodinger.com). Further
receptor refinements were carried out utilizing ProteinPrep from within Maestro. Investigation
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of inhibitor binding modes were performed using Glide[18] and Qsite[19] jointly for quantum
polarized ligand docking. This method generates highly accurate binding modes by quantum
mechanically calculating the partial atomic charges of the docked ligand using B3LYP/6-31G*
within the receptor and subsequently re-docking the ligand [20, 21].
DFT investigation of Cα-H dissociation energies
The bond dissociation energies of Cα-H for all cinnamic acid analogs were calculated
using Jaguar [22].

DFT calculations were performed with the B3LYP hybrid exchange-

correlation functional and the 6-31G* basis set.

The geometries were optimized for all

molecules in the gas phase. The Cα-H bond was then increased from 1.08 – 3.0 Ǻ while holding
the molecule rigid (Figure 3.2), and single point energies were calculated
Inhibition of O2 consumption from N-acetylglycine by cinnamic acid
Reactions at 37.0 ± 0.1 °C were initiated by the addition of PAM (35 µg) into 2.0 ml of
100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10
µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, 1.0 – 45 mM Nacetylglycine, and 0-9 mM cinnamic acid. Initial rates were measured by following the PAMdependent consumption of O2 using a Yellow Springs Instrument Model 5300 oxygen monitor.
Inactivation of PAM by cinnamic acid
Inactivation reactions of 100 µL containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl,
1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0
mM sodium ascorbate, and 0-3 mM cinnamic acid were initiated by the addition of enzyme and
incubated at 37 °C. Aliquots of 15 µL were withdrawn at various intervals and diluted into 2.0
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mL reactions containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001%
(v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and
20 mM N-acetylglycine and monitored for O2 consumption.
Reversibility of inactivation
An inactivation reaction of 250 µL containing 100 mM MES/NaOH pH 6.0, 30 mM
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM

Cu(NO3)2, 5.0 mM sodium ascorbate, and 7 mM cinnamic acid was initiated by the addition of
enzyme and incubated at 37 °C for 2 hours. The reaction was then extensively dialyzed and
concentrated to 50 µL. The concentrate was then used to initiate a 1.0 mL reaction containing
100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, and
10 mM hippurate. At various time intervals, a 100 µL aliquot was removed, added to a vial
containing 20 µL of 6% (v/v) TFA to terminate the reaction, and the concentration of glyoxylate
formed measured in the acidified samples to test for the recovery of activity.
PAM labeling by dansyl-4-aminocinnamic acid
Covalent modification of PAM was investigated by using dansyl-4-aminocinnamic acid,
a fluorescent molecule, as an inactivator. A 0.5 mL reaction containing 100 mM MES/NaOH pH
6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0
µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 1.0 mM dansyl-4-aminocinnamic acid was
initiated by the addition of 50 µg of enzyme and incubated at 37 °C for 3 hours. The reaction
mixture was dialyzed against 100 mL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v)
ethanol, and 0.001% (v/v) Triton X-100 for 4 hours changing the dialysis buffer every hour. The
reaction mixture was then concentrated by ultra-filtration to ~100 µL. This sample was then
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trypsin digested and the peptide fragments were analyzed by RP-HPLC utilizing a fluorescence
detector.
PAM labeling by 14C-cinnamic acid

Enzyme modification was also examined using radio-labeled cinnamic acid. A 250 µL
reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v)
Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 3 µCi
of

14

C-cinnamic acid was initiated by the addition of 18 – 52 µg of PAM. The reaction was

allowed to incubate at 37 °C for 3 hours before ultra-filtration was performed. The reaction was
then washed with 200 µL of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, and
0.001% (v/v) Triton X-100 and ultra-filtration repeated.

The underside of the filtration

membrane was then washed with poly(ethylene glycol) to remove excess non-enzyme bound
radio-labeled cinnamic acid.

Counts per minute were then compared using a scintillation

counter.
PAM modification through inactivation by cinnamic acid
Modification of the PAM active site by the reactive Cu/O species was also investigated as
a possible means of cinnamic acid mediated inactivation. A 100 µL reaction containing 100 mM
MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 µM
Cu(NO3)2, 5.0 mM sodium ascorbate, and 3 mM cinnamic acid was initiated with 20 µg of PAM
and incubated at 37 °C for 12 hours.

The enzyme was then dialyzed against 100 mM

MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100 for 4 hours and
the volume reduced to ~40 µL by ultra-filtration. The enzyme was then analyzed by MALDITOF against control for any modification. The reaction was then repeated as previously stated
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followed by trypsin digestion. The reaction was then analyzed by LC/MS, LC/MS/MS, and
MALDI-TOF.
PAL inactivation assay

To determine if the cinnamic acid was also inactivating PAL activity by PAM, initial rates of
glyoxylate formation from α-hydroxyhippurate, a known PAL substrate, were monitored.
Reactions of 20 µg of PAM in a 100 µL solution containing 100 mM MES/NaOH pH 6.0, 30
mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, and a concentration of cinnamic acid
or analog equal to 5-times KI of PHM-related inhibition for that particular inhibitor were
incubated for 2 hours. A 20 µL aliquot was removed and used to initiate a 1.0 mL reaction
containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton
X-100, and 10 mM α-hydroxyhippurate. At 10 minute intervals from 10 to 60 min., a 100 µL
aliquot was removed, added to a vial containing 20 µL of 6% (v/v) TFA to terminate the
reaction, and the concentration of glyoxylate formed measured in the acidified samples.
Glyoxylate was determined by the spectrophotometric method of Christman et al. [23] as
modified by Katopodis and May [24]. Standard curves of [glyoxylate] vs. A520 were constructed
in the appropriate buffers using a glyoxylate solution that had been calibrated by measuring the
3

-1

-1

glyoxylate-dependent oxidation of NADH (∆ε340 = 6.22 x 10 M cm ) as catalyzed by lactate
dehydrogenase.
Analysis of steady-state kinetic data
Initial rate studies that resulted in competitive inhibition were also analyzed by
Kaleidagraph® fit of v vs. [S] as a function of inhibitor concentration to equation 1.
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(1)

Where KM,app is the apparent Michaelis constant for the oxidizable substrate at fixed [ascorbate]
and ambient [O2] concentrations and VMAX,app is the apparent maximum initial velocity at
saturating [S].
Inactivation kinetics were analyzed by Kaleidagraph® fit of 1/kobs vs 1/[ I ] to equation 2.

(2)

Where kobs is the observed rate of inactivation, and kinact is the intrinsic rate of inactivation of
enzyme.
Results
Cinnamic acid and analogs as inhibitors of PAM
Cinnamic acid and several analogs were initially investigated as small molecule
inhibitors of PAM.

Cinnamic acid was shown to inhibit the consumption of O2 from N-

acetylglycine in a competitive manner (Figure 3.3) yielding the steady-state kinetic values as
described by equation 1 (Table 3.1). All cinnamic acid analogs were assumed competitive and
also analyzed according to equation 1.
Inactivation of PAM by cinnamic acid
Cinnamic acid was investigated as an inactivator of PAM by the dilution method, a
common method for determining the kinetic parameters of time-dependent inactivators [25].
65

Chapter Three: Cinnamic Acid Derivatives as Inactivators of PAM

Inactivation experiments performed with cinnamic acid indicated that it is a time-dependent

inactivator of PAM (Figure 3.4). The inactivation was pseudo first-order and concentration
dependent, as well as O2- and ascorbate-dependent (Figure 3.5). Substrate was also found to
protect against inactivation of PAM by cinnamic acid. Perdeuterated cinnamic acid was also
investigated in search of an isotope effect on kinact as evidence for H-abstraction, though one was
not observed (Table 3.2).
Inactivation of PAL activity
Cinnamic acid and analogs were tested as PAL inactivators as well to investigate whether
or not the PAM activation occurring was specific to the PHM domain. The experiment indicates
that PAL is completely unaffected by cinnamic acid and the various analogs tested and retained
100% activity when compared to the control reaction (Figure 3.6).
Irreversible inactivation
Cinnamic acid was able to irreversibly inactivate PAM. Extensive dialysis of a reaction
mixture incubated with cinnamic acid yielded dead enzyme incapable of producing glyoxylate
from hippuric acid (Figure 3.7).
Non-labeled PAM
Multiple experiments were performed in an attempt to verify covalent linkage of
cinnamic acid to PAM. Both the fluorescent labeling with dansyl-4-aminocinnamic acid, and the
radio labeling experiments indicated that cinnamic acid was not covalently linking to the
enzyme. Multiple methods of mass analysis were performed in an attempt to elucidate any autooxidation or hydroxylation of the PAM active site as has been hypothesized in earlier studies
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with 4-phenyl-3-butenoic acid [26]. However, we were unable to detect any modification of the
enzyme after exhausting all efforts and resources (Figure 3.8).
Docking of cinnamic acid and analogs
Docking of the investigated compounds yielded poses in agreement with the competitive
nature of inhibition observed experimentally.

The compounds bind forming a salt bridge

between the carboxy terminus and the guanidino group of R240 as has been previously shown
with glycine-extended substrates [27]. This interaction aligns the Cα-H in close proximity to
CuM (Figure 3.9). However, the lack of glycyl amide hydrogen to H-bond with the N316 oxygen
coupled with the compounds’ small size preventing any interaction with the nearby hydrophobic
pocket would allow for a great deal of movement within the active site making hydrogen
abstraction difficult.
Computation results for bond energy
The ab initio calculations performed to estimate the bond dissociation energies of the CαH bond for cinnamic acid and the investigated analogs indicate that more than 110 kcal/mol are
needed (Table 3.3).
Discussion
Cinnamic acid is a structural analogue of 4-phenyl-3-butenoic acid (PBA), a welldocumented mechanism-based, irreversible inhibitor (inactivator) of the PHM domain as both
molecules contain an olefin moiety [16, 24]. While PBA has been suggested to be hydroxylated
at bo th the α and γ p osition s b y PHM [26], none of the compounds tested within this study
displayed oxygen consumption when screened for activity even though inactivation was O2- and
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ascorbate-dependent. Further evidence that hydroxylation was absent with cinnamic acid was

the lack of a deuterium kinetic isotope effect for kinact or kinact/KI. Although the presence of an
isotope effect would give evidence for hydrogen abstraction from the Cα of cinnamic acid,
absence may suggest that the magnitude of Dkinact may be suppressed by much faster steps in the
mechanism. The lack of PHM inactivation with 3-phenyloxirane-2-carboxylic acid suggests that
C-H cleavage is required to generate the inactivating olefin intermediate species in the
hydroxylation pathway. The C-H bond dissociation energies, displayed in Table 3.3, display
enthalpies for each conjugated species to be very close to each other (a difference of only 13
kcal/mole). Therefore, if the inactivation species were ultimately dependent only on a C-H
cleavage step, 3-phenyloxirane-2-carboxylic acid would be expected to inactivate PHM. This
suggests that the inactivation is dependent on the presence of an olefin while the lack of
inactivation by phenylpropiolic acid, the alkyne derivative, suggests that the Cα-H is also a
prerequisite for inactivation. This may suggest that the inactivating species is an intermediate
along the hydroxylation pathway after the abstraction of the Cα-H and that the inactivation is
dependent on the olefin. This species may be a vinyl radical present on the Cα as this radical
would not delocalize.
The instrumental nature of the olefin radical generated upon hydrogen abstraction further
suggest that dynamical freedom of this small inactivator may also be important to this
inactivation mechanism. The modeling performed suggests that there are few interactions to
hold cinnamic acid in the active site other than the salt-bridge with R240. This is also reflected
in the poor KI value for cinnamic acid (3.6 mM, Table 1). This may be directly attributed to the
lack of amide hydrogen to anchor the Cα-H and properly position it for abstraction along with
the inability of the phenyl ring to bury itself into the hydrophobic pocket to further stabilize the
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molecule. This results in a significant increase in the conformational sampling and a decrease in
the probability of proper wave function overlap between donor and acceptor [28].

Upon

successful hydrogen abstraction, the radical character generated can be shared between α and β
carbons. Assuming the Cu-alkoxide intermediate, hydroxylation of such a mobile species with
delocalized radical character would prove difficult. Thus, the reactive cinnamic acid species
may leave the active site allowing for hydroxylation to occur by the addition of water to the
radical intermediate. This would leave the activated Cu-oxo species to either modify the enzyme
in a way undetectable by mass analysis or perhaps linger in a trapped dynamic state unable to
return to the free-enzyme state (Figure 3.10).
Conclusion
In conclusion, we have demonstrated that potential diabetes drug candidates are capable
of PAM inactivation. Because of the importance of PAM in the biosynthesis of amidated peptide
hormones, these results are of great pharmacological significance. As the development of smallmolecule insulin secretion drugs with the α,β olefin moiety progresses, special attention must be
paid to the possible inactivation of PAM. These findings are also therapeutically relevant as
PAM is over-expressed in both small cell lung cancer and prostate cancer [29-31] making it a
possible drug target.
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Figure 3.2. Illustration of carbon-hydrogen bond elongation for the DFT calculation of
bond dissociation energies.
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Figure 3.3. Inhibition of PAM by cinnamic acid. Initial rates were determined at 37 ◦C as
described in the Materials and Methods section. The points are experimentally determined
initial rates. The lines were computer fit to the data using equation 1.
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Figure 3.4. Inactivation plots for cinnamic acid. Experiments were performed as indicated
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PAL Inactivation by cinnamic acid and Derivatives: Glyoxylate Assay
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Figure 3.6. Cinnamate analogs as inactivators of the PAL activity of PAM by the glyoxylate
assay.
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Reversibility of Inactivation by Cinnamic acid: Glyoxylate Assay
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Figure 3.7. Reversibility of inactivation of PAM by cinnamic acid.
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Figure 3.8. MALDI-TOF overlay of Trypson-digested active (blue) and cinnamateinactivated (green) PAM.
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Figure 3.9. Cinnamate docked in the active site of the PHM crystal structure (1SDW).
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Table 3.1. Inhibition constants calculated from computer fit of data to equation 1.
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Table 3.2. Inactivation constants calculated by Kitz-Wilson analysis using the dilution assay
method as outline in the materials and methods section.
kinact (min-1)

kinact/KI (mM-1 min-1)

Cinnamic acid

0.15 ± 0.02

0.04 ± 0.006

N,N-dimethylaminocinnamic acid

0.08 ± 0.01

0.03 ± 0.005

4-aminocinnamic acid

0.03 ± 0.005

0.06 ± 0.01

Dansyl-4-aminocinnamic acid

0.21 ± 0.03

19.1 ± 3.2

Perdeuterated cinnamic acid

0.15 ± 0.01

0.04 ± 0.004

Compound
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Table 3.3. Calculated bond dissociation energies of selected cinnamate analogs by DFT/6-31G*.
Structure

Name

HO

kcal/mol

Cinnamic acid

114

Dns-4-aminocinnamic acid

116

3-phenyloxirane-2-carboxylic acid

117

4-aminocinnamic acid

123

4-nitrocinnamic acid

127

O

N

O

S

O

NH

HO

O

O

HO
O

HO

O

NH2

HO

O

NO2
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Chapter Four: PAM Inactivation by Phenylbutenoates:
Evidence for a radical intermediate

Peptidylglycine α-amidating monooxygenase (PAM) is a bifunctional metalloenzyme
responsible for the conversion of glycine-extended peptide prohormones to the active hormone,
peptide-amide [1, 2]. Catalysis proceeds through the abstraction of the glycyl Cα hydrogen via a
reactive Cu-oxo species followed by hydroxylation, and finally the cleavage of the N-Cα bond to
yield glyoxylate and the peptide-amide.

Two domains in PAM are responsible for this

chemistry. The peptidylglycine α-hydroxylating monooxygenase (PHM) domain is responsible
for the hydrogen abstraction and subsequent hydroxylation while the peptidylglycine
amidoglycolate lyase (PAL) domain is responsible for the cleavage of the N-Cα bond (Figure
4.1) [3]. PHM activity is copper-, ascorbate-, and O2-dependent while PAL catalysis is zinc-,
calcium-, and iron-dependent [4-9].
PHM and its sister enzyme dopamine β-monooxygenase (DβM) are mechanistically
related.

Both PHM and DβM produce essential signaling molecules which are stored in

secretory granules and used for intercellular communication [10]. They catalyze very similar
reactions utilizing a reactive copper-oxygen species to hydroxylate their very different respective
substrates (Figure 4.2). PHM and DβM are essential enzymes as genetically engineered mice
and Drosophila melanogaster lacking a functional PHM or DβM gene generally die as embryos
[11-13]. PAM/PHM and DβM have been the focus of much mechanistic study. Many of the
proposed mechanistic schemes involve a substrate free radical intermediate (Figure 4.3). All of
the work providing evidence for this radical intermediate has been performed on DβM. Several
studies in particular have provided evidence for a substrate radical mechanism in DβM [14-17].
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No su ch stu dies have been p erformed with PHM thou g h the results of the DβM stu d ies have
been applied towards the elucidation of both mechanisms.

Here we report experiments that provide evidence for a radical intermediate in PAM
catalysis. Ring-substituted suicide substrates are used to probe electronic effects to define the
nature of the reactive intermediate. The results provide evidence for a radical mechanism and
are in agreement with previous studies performed on DβM.
Materials and Methods
Materials
4-Phenyl-3-butenoic acid and N-acetylglycine were from Sigma Aldrich.

4-(4-

chlorophenyl)-3-butenoic acid, 4-(4-methoxyphenyl)-3-butenoic acid, 4-(3-chlorophenyl)-3butenoic acid, and 4-(3-methoxyphenyl)-3-butenoic acid were a gift from Dr. John Vederas.
Bovine catalase was from Worthington.

Recombinant rat PAM was a gift from Unigene

Laboratories, Inc. All other reagents were of the highest quality commercially available.
In silico docking
The crystal structure for reduced peptidylglycine α-hydroxylating monooxygenase
(PHM) was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, 1SDW) [18]. All
species deemed superfluous for ligand binding were removed from the pdb file (nickel, water,
glycerol, and substrate). Formal charges for enzyme-bound copper ions were set as 1, bond
orders were corrected, and hydrogens were added using Maestro (www.schrodinger.com).
Further receptor refinements were carried out utilizing ProteinPrep from within Maestro.
Investigation of the phenylbutenoate binding modes were performed using Glide[19] and
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Qsite[20] jointly for quantum polarized ligand docking. This method generates highly accurate
binding modes by quantum mechanically calculating the partial atomic charges of the docked
ligand using B3LYP/6-31G* within the receptor and subsequently re-docking the ligand [21, 22].
Radical stabilization energies
To investigate the effects of the substituents on the relative stability of the Cα radical, ab
initio molecular orbital theory and density functional theory calculations were performed using
PCGAMESS. The geometries of each phenylbutenoate and the corresponding radical along with
methane and the methane radical were determined at the B3LYP/6-31G(d) level. Single point
energy calculations were then carried out on the optimized structures at the MP2 level with 6311+G(2df,p) basis sets. Radical stabilization energies of PBA radicals were calculated as
energies of the following reaction:

(1)
Thus, the difference between the C—H bond dissociation energy of methane and the C—H bond
dissociation energy in the phenylbutenoates.
(2)
A positive radical stabilization energy value would then indicate that the radical is stable relative
to the methane radical compared with the corresponding closed-shell systems.
Inactivation of PAM by 4-phenyl-3-butenoates at ambient O2
Inactivation reactions of 50 µL containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl,
1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0
mM sodium ascorbate, and various concentrations of phenylbutenoates were initiated by the
addition of enzyme and incubated at 37 °C. Aliquots of 20 µL were withdrawn at various
intervals and diluted into 2.0 mL reactions containing 100 mM MES/NaOH pH 6.0, 30 mM
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NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM
Cu(NO3)2, 5.0 mM sodium ascorbate, and 20 mM N-acetylglycine. The residual activity was
thus measured by the rate of oxygen consumption.

Because of the high potency of the

phenylbutenoates, the inactivation reactions were not performed continuously due to the down
time required to prepare the next reaction mixture within the oxygen electrode chamber. Thus, a
separate reaction was required for each time-point at each concentration.
Inactivation of PAM by 4-phenyl-3-butenoates at variable O2 concentrations
Inactivation stock reactions of 200 µL containing 100 mM MES/NaOH pH 6.0, 30 mM
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM
Cu(NO3)2, 5.0 mM sodium ascorbate, and various concentrations of phenylbutenoates were
incubated at 37 °C for 10 minutes in septum sealed tubes. The rubber septum was then pierced
with a 25 gauge needle as a pressure release and a second needle attached to non-permeable
rubber tubing. Through this tubing, the desired concentration of O2 was delivered by means of
an ACS certified O2:N2 mixture. The delivery needle was submerged in the reaction solution to
“bubble through” the gas mixture. Bubbling of the gas mixture through the reaction solution
prevented the evaporation of reaction mixture that was noted when blowing over the gas mixture
while stirring the solution. While the total volume change related to this evaporation was small
in absolute terms (20 – 40 µL), it was significant relative to the total reaction volume making the
inactivator concentrations unreliable. The thin gauge needle allowed for sufficient aeration of
the samples providing both accurate concentrations of O2. After streaming the gas mixture
through the reaction sample for 5 minutes, one empty reaction tube was prepared with rubber
septum for each time point to be taken at that particular inactivator concentration. A typical
inactivation study by the dilution method is classically a continuous assay. However, the time
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required to prepare the oxygen electrode in between time points rendered a continuous assay
method impossible. Thus, each time point required the preparation of a new reaction mixture

and the incubation was repeated from time = 0. Each empty reaction tube with septum was then
purged with the desired O2:N2 reaction mixture and the needles removed. 30 µL of the stock
reaction was then placed into each purged tube with a 25 gauge needle and syringe. Each
reaction was then initiated with enzyme and incubated for the desired length of time before
removing a 20 µL aliquot and initiating a 2.0 mL reaction containing 100 mM MES/NaOH pH
6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0
µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 20 mM N-acetylglycine and monitoring O2
consumption to examine residual enzyme activity.
Reversibility of Inactivation
An inactivation reaction of 100 µL containing 100 mM MES/NaOH pH 6.0, 30 mM
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM
Cu(NO3)2, 5.0 mM sodium ascorbate, and 100 µM 4-phenyl-3-butenoic acid was initiated by the
addition of enzyme and incubated at 37 °C for 2 hours. The reaction was then extensively
dialyzed and concentrated to ~50 µL. The concentrate was then used to initiate a 1.0 mL
reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001%
(v/v) Triton X-100, and 10 mM hippurate. At various time intervals, a 100 µL aliquot was
removed, added to a vial containing 20 µL of 6% (v/v) TFA to terminate the reaction, and the
concentration of glyoxylate formed measured in the acidified samples to test for the recovery of
activity.
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Inactivation of PAL activity by 4-phenyl-3-butenoic acid

To determine if 4-phenyl-3-butenoic acid was also inactivating PAL activity of PAM,
initial rates of glyoxylate formation from α-hydroxyhippurate, a known PAL substrate, were
monitored. Reactions of 20 µg of PAM in a 100 µL solution containing 100 mM MES/NaOH
pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, and 100 µM 4-phenyl-3butenoic acid was incubated for 2 hours. A 20 µL aliquot was removed and used to initiate a 1.0
mL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001%
(v/v) Triton X-100, and 10 mM α-hydroxyhippurate. At various time intervals, a 100 µL aliquot
was removed, added to a vial containing 20 µL of 6% (v/v) TFA to terminate the reaction, and
the concentration of glyoxylate formed measured in the acidified samples.
Determination of partition ratios
To determine the partition ratio for product formation versus enzyme inactivation, a 2.0
mL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1% (v/v) ethanol, 0.001%
(v/v) Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and
1 mM of the desired 4-phenyl-3-butenoic acid derivative.

Oxygen consumption was then

monitored by oxygen electrode to monitor hydroxylation activity.
Determination of glyoxylate concentration
Glyoxylate was determined by the spectrophotometric method of Christman et al. [23] as
modified by Katopodis and May [24]. Standard curves of [glyoxylate] vs. A520 were constructed
in the appropriate buffers using a glyoxylate solution that had been calibrated by measuring the
3

-1

-1

glyoxylate-dependent oxidation of NADH (∆ε340 = 6.22 x 10 M cm ) as catalyzed by lactate
dehydrogenase.
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Investigation of inactivation through PAM modification

Modification of the PAM active site by the activated Cu/O species was investigated as a
possible means of phenylbutenoate mediated inactivation in addition to covalent labeling by
phenylbutenoate. A 100 µL reaction containing 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1%
(v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 µM Cu(NO3)2, 5.0 mM sodium ascorbate, and 500
µM 4-phenyl-3-butenoic acid was initiated with 20 µg of PAM and incubated at 37 °C for 12
hours. The enzyme was then dialyzed against 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1%
(v/v) ethanol, 0.001% (v/v) Triton X-100 for 4 hours and the volume reduced to ~40 µL by ultrafiltration. The enzyme was then analyzed by MALDI-TOF against control for any modification.
The reaction was then repeated as previously stated followed by trypsin digestion. The reaction
was then analyzed by both LC/MS and MALDI-TOF.
Analysis of kinetic data
Inactivation kinetics were analyzed by Kaleidagraph fit of 1/kobs vs 1/[ I ] to equation 3.

(3)

where kobs is the observed rate of inactivation, and kinact is the intrinsic rate of inactivation of
enzyme.
Results
Molecular modeling
The phenylbutenoates of interest were docked into the reduced PHM crystal structure.
As expected, the terminal carboxylate formed a salt-bridge with R240 (Figure 4.4). The Cα-H is
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in close proximity to the catalytic active site copper, CuM (Figure 4.5). The phenylbutenoates are
not large enough, however, for the phenyl groups to bury themselves into the hydrophobic
pocket to restrict movement of the molecule. The small size in addition to the lack of an amide
hydrogen needed for hydrogen bonding to N316 to further limit ligand mobility within the active
site allows for a great deal of movement of the phenylbutenoates once within the active site.
Molecular dynamics simulations performed with the docked 4-phenyl-3-butenoate using NAMD
2.6 demonstrate that there is, indeed, a great deal of mobility for these small compounds without
the requisite interactions present when peptide-gly substrates are bound to PAM.
Partition ratios
The partition ratios for the ring-substituted phenylbutenoates were determined by
measuring the total oxygen consumed during inactivation as a stoichiometric amount is O2 is
consumed during hydroxylation. Thus, upon complete inactivation the amount of O2 consumed

is equivalent to the amount of hydroxylated phenylbutenoate produced. All phenylbutenoates
investigated are efficient inactivators with the most efficient giving a partition ratio of 18
turnovers per inactivation (Table 4.1).
Inactivation of PAM by phenylbutenoates
Several ring-substituted phenylbutenoates were investigated as inactivators of PAM by
the dilution method, a common method for determining the kinetic parameters of time-dependent
inactivators [25]. Inactivation experiments performed with these analogs indicated that they are
indeed time-dependent inactivators of PAM (Figure 4.6). The inactivation was pseudo firstorder and concentration dependent, as well as O2- and ascorbate-dependent. Substrate was found
to protect against inactivation of PAM by 4-phenyl-3-butenoic acid (Figure 4.7).

The

inactivation was found to be irreversible. Extensive dialysis of a reaction mixture incubated with
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4-phenyl-3-butenoic acid yielded dead enzyme incapable of producing glyoxylate from hippuric

acid and no oxygen consumption was observed when monitored with the oxygen electrode. The
kinetic parameters for inactivation under ambient conditions are listed in Table 4.2.
The ring-substituted phenylbutenoates were then further examined to investigate the
effects of substitution on the partition ratio, Vmax/kinact, and the kinetics of inactivation. A double
reciprocal plot of 1/kobs vs. 1/[PBA] at fixed O2 concentrations yields a pattern of intersecting
lines
(3)

with a slope of:
(4)

and the ordinate intercept of:
(5)

A replot of the intercept vs. 1/[O2] yields a straight line. From the inactivation kinetics at
varying concentrations of O2, a linear free energy plot of

values can be constructed as

a function of electron-withdrawing or electron-donating ability of the substituent (Figure 4.8).
Inactivation of PAL activity
4-Phenyl-3-butenoic acid was tested as a PAL inactivator as well to investigate whether
or not the PAM inactivation occurring was specific to the PHM domain. Glyoxylate was readily
formed from α-hydroxyhippurate, a known PAL substrate. The experiment indicates that PAL is
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completely unaffected by 4-phenyl-3-butenoic acid and retained 100% activity when compared
to the control reaction (Figure 4.9).
Non-labeled PAM

Multiple methods of mass analysis were performed in an attempt to elucidate any autooxidation or hydroxylation of the PAM active site as has been hypothesized in earlier studies
with 4-phenyl-3-butenoic acid [26]. While the hydroxylated product was detected by LC/MS,
we were unable to detect any modification of the enzyme by MALDI-TOF, or LC/MS and
LC/MS/MS on trypsin digested samples (Figure 4.10).
Radical stabilization energies
The radical stabilization energies calculated from the isodesmic reaction discussed
previously indicate that several of the phenylbutenoates are capable of forming extremely stable
radicals when compared to the methane radical [27]. While the radical stabilities are relative and
not absolute, the data indicates that the 4-(4-chlorophenyl)-3-butenoic acid and 4-(4methoxyphenyl)-3-butenoic acid derivatives are greater than an order of magnitude more stable
than the other phenylbutenoates analogs investigated (Table 4.3).

These two very stable

derivatives also had the highest partition ratios. Thus, there exists a direct correlation between
radical stability and the ability of PHM to hydroxylate the phenylbutenoates after hydrogen
abstraction.
Discussion
The phenylbutenoates investigated meet the criteria for mechanism-based inhibitors of
PAM. The inactivation is both ascorbate- and O2- dependent. The phenylbutenoates all act as
suicide substrates under turnover conditions inactivating the enzyme.
protected against by the presence of substrate.
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The experiments performed were designed to give evidence of a radical intermediate
being formed during PAM catalysis. To accomplish this, the kinetics of inactivation and the

partition ratios were examined using phenylbutenoates with substituents on the phenyl ring of
different electron-donating and electron-withdrawing effects. The steady-state kinetics of PAM
with PBA can be described as

A minimal mechanism accounting for catalysis and inactivation is described as
Cu(II)

k1[Asc]2

Cu(II)

k2

E

Cu(II)

E

Cu(II)

2Asc

k3

E

Cu(I)

k5[PBA]

Cu(I)

k6

E

Cu(I)
Cu(I)

PBA

k7[O2]
k8

Cu(I)

E

Cu(I)

PBA O2

k9

EX

k11

Cu(II)

k15

k13

E

Cu(II)

E

Cu(II)

DEAD

E

Cu(II)

.

For this inactivation scheme, the rate constant for the catalytic steps is k9.
kinetic parameter that contains the catalytic step and would equal
ratio for inactivation for a mechanism-based inhibitor is

is then the
. The partition

. Thus, one can arrive at

by simply multiplying the partition ratio by the inactivation kinetic data; this allows the
attainment of steady-state kinetic data when such data cannot be obtained directly. Therefore,
we have multiplied the partition ratios by the respective
phenylbutenoates to calculate the

values of the

values. A free energy plot was then created with these

values and compared to various sigma constants for each substituent (Figure 4.11). The different
sigma constants differ in that they are based on different standard reaction series.
compared to σ+, a ρ value of -1.03 was obtained.
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Similar studies have previously been performed on D-amino acid oxidase.

This

flavoprotein was found to go through a carbanion intermediate [28]. The ρ value obtained when
Vmax was measured for a series of ring-substituted phenylglycines was 5.44 [29]. This finding
suggests that PAM does not proceed through a carbanion mechanism. That PAM proceeds via a
radical mechanism is consistent with the data which shows a small absolute magnitude for the
valu e of ρ and also the correlation with σ+, results characteristic of a radical mechanism [14].
Studies on styrene derivatives involving allylic hydrogen abstraction through a radical
mechanism have demonstrated similar results, finding a Hammett slope ρ = -0.82 [30].
The partition ratios and relative radical stabilities calculated using ab initio methods also
support a radical mechanism. The partition ratios are all within an order of magnitude. The
agreement seen between the radical stability of the two most stable phenylbutenoates calculated
and that they are also the two ligands with the highest partition ratios provides further evidence
that catalysis proceeds via a radical mechanism. The increased stability for the radical on the Cα
allows for a greater ease in hydroxylation by the PHM domain in PAM. This leads to more
turnovers before inactivation occurs.
Conclusion
In conclusion, we report here findings that suggest PAM catalysis occurs through a
radical mechanism. Other studies have shown that two hydroxylation products are formed
during phenylbutenoate catalysis leading to both the alpha and gamma hydroxylated derivatives
[26]. The most likely mechanism by which this hydroxylation may proceed is through the
resonance of a radical generated at the alpha position during hydrogen abstraction (Figure 4.12).
The dynamical freedom allowed the phenylbutenoate from the lack of amide-hydrogen to N316
hydrogen bonding, an interaction present in the peptide-gly substrates (Figure 4.13), has been
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hypothesized to cause the lack of absolute stereospecificity in hydroxylation of the 2-position

observed in earlier studies [26]. This mobility coupled with the resonance of the radical may
reduce the probability of hydroxylation at the 2-position allowing for release of the PBA radical
intermediate leaving an activated oxygen at CuM. This would also allow for autoxidation of the
active site resulting in inactive enzyme. Water would then be the hydroxylating species for the
4-OH-PBA species.
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Figure 4.4. 4-phenyl-3-butenoate forming a salt bridge with the guanidino group of R240.
The secondary structure is rendered as a transparent ribbon in orange. Note that carbon is
teal, nitrogen is blue, oxygen is red, and hydrogen is white.
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O

OH

PBA

R240

N316

Figure 4.5. 4-phenyl-3-butenoate shown docked within the PHM active site showing the
proximity of the Cα-H to the CuM. A lack of interaction with N316 should also be noted.
Note that carbon is teal, nitrogen is blue, oxygen is red, sulfur is yellow, hydrogen is white,
and copper is orange.
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Figure 4.6. The time-dependent inactivation of PHM activity by 4-(3-chlorophenyl)-3butenoic acid.
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Figure 4.7. Substrate was shown to protect against inactivation by 4-phenyl-3-butenoic
acid.
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Figure 4.8. Linear free energy plot of kinact/KO2 values as a function of electron-withdrawing
or electron-donating ability of the substituent.
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Figure 4.9. The effect of 4-phenyl-3-butenoic acid on the PAL activity of PAM.
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Figure 4.10. The trypsin digested MALDI-TOF fingerprint of normal (blue) and 4-phenyl3-butenoic acid inactivated (green) PAM.
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Figure 4.11. Free energy plot of Vmax/KO2 as a function of electron-withdrawing and
electron-donating ability of the substituent.
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Figure 4.12. Radical rearrangement between alpha and gamma positions in 4-phenyl-3butenoic acid leading to two hydroxylated products.
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Figure 4.13. Benzylglycine docked to illustrate the proper hydrogen bonding interaction
between N316 and the amide-hydrogen of the substrate.
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Table 4.1. Partition ratios for ring-substituted 4-phenyl-3-butenoic acids
Name

Partition Ratio

4-phenyl-3-butenoic acid

85

4-(4-chlorophenyl)-3-butenoic acid

94

4-(3-chlorophenyl)-3-butenoic acid

35

4-(4-methoxyphenyl)-3-butenoic acid

143

4-(3-methoxyphenyl)-3-butenoic acid

18
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Table 4.2. The kinetic parameters for the inactivation of PHM by ring-substituted 4-phenyl-3butenoic acids.
kinact (min-1)

KI (mM)

4-phenyl-3-butenoic acid

4.18

0.004

4-(4-chlorophenyl)-3-butenoic acid

13.6

0.98

4-(3-chlorophenyl)-3-butenoic acid

1.18

1.45

4-(4-methoxyphenyl)-3-butenoic acid

0.22

0.06

4-(3-methoxyphenyl)-3-butenoic acid

0.10

0.04

Name
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Table 4.3. Radical stabilization energies for ring-substituted 4-phenyl-3-butenoic acids.
Name

RSE (kcal/mol)

4-phenyl-3-butenoic acid

47.6

4-(4-chlorophenyl)-3-butenoic acid

1480

4-(3-chlorophenyl)-3-butenoic acid

53.9

4-(4-methoxyphenyl)-3-butenoic acid

1440

4-(3-methoxyphenyl)-3-butenoic acid

49.5
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Peptidylglycine α-amidating monooxygenase (PAM) is a copper- and zinc-dependent,
bifunctional enzyme that catalyzes the cleavage of glycine-extended peptides to the
corresponding amides and glyoxylate[1, 2]. The sequential action of hydroxylating the glycyl αcarbon and then cleaving the carbon-amide bond are dependent upon the peptidylglycine αhydroxylating monooxygenase (PHM) and peptidylglycine amidoglycolate lyase (PAL)
domains, respectively (Figure 5.1) [3-11].
PAM is responsible for activating peptide prohormones in vivo. Although a considerable
body of mechanistic and structure/function data has been generated in an attempt to understand
this redox chemistry [12-17], there are still crucial unanswered questions regarding electron
transfer, dioxygen activation, and radical formation during C-H bond cleavage that preclude a
comprehensive understanding of glycine hydroxylation. Crystallographers have stated that the
reduction of PAM by ascorbate is collisional as they have been unable to identify a binding site
for ascorbate.

Mimosine, however, has been shown to be a competitive inhibitor against

ascorbate suggesting that a binding site must exist [18].
This work attempts to elucidate possible binding sites for ascorbate using all-atom
molecular dynamics simulations.

Steered molecular dynamics (SMD) simulations are also

employed in an attempt to confirm the computationally discovered binding sites of ascorbate by
comparing the experimentally determined KM with the potential of mean force calculated using
the Jarzynski relation. In SMD simulations, external forces are applied in a time-dependent
manner to, for example, a ligand to facilitate unbinding from an active site. One can analyze the
interactions of the unbinding ligand with the pocket, and the applied forces and ligand position as
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a function of time yielding important structural information about the binding mechanism and

structure-function relationships of the ligand-receptor complex [19]. By utilizing the Jarzynski
relationship, one can relate the average potential of mean force derived from a series of SMD
simulations to the average difference in free energy of two equilibrium states.
The Jarzynski relationship allows for the use of non-equilibrium calculations of
equilibrium free energies. In 1997, Jarzynski proved that:

where ΔG is the Gibbs free energy difference, β is 1/kBT, Wi is the out of equilibrium work done
onto the system when going from state A to state B, and the exponential average is done over an
equilibrium ensemble only for state A. The only requirements for this equality to work are that
the initial ensemble over state A be equilibrated, and that the exponential average be converged.
There is, however, no requirement as to how the switch from state A to state B should be done
(Figure 5.2).
Computationally, this is the power of the Jarzynski relationship as there are no
requirements for how slowly one must switch from state A to state B. The real advantage of
employing the Jarzynski relationship is that one only needs to equilibrate the initial state. This
eliminates the necessity for a slow, quasi-static transformation from state A to state B. In an era
of massively parallel computers available for short spans of time, this type of simulation is ideal
where a complete Jarzynski style computation can be submitted in parallel and all data collected
in the time of one simulated pulling. When small counts of CPUs are available for long periods
of time, other methods may be preferred.
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Equilibrium Molecular Dynamics
The PHM crystal structure (1SDW) was first obtained from the Protein Databank, and all
catalytically superfluous molecules and ions were removed. The force field parameters for both
Cu2+ domains were determined by normal mode analysis in the harmonic approximation. The
Hessian was calculated for each methyl-capped Cu-containing fragment (Figure 5.3) separately
using Density Functional Theory to obtain the bonding and bending force constants. DFT
calculations were performed with the B3LYP hybrid exchange-correlation functional and the 631G* basis set. The equilibrium bond distances were found via geometry optimization. The
partial charges of the coppers were the formal charges expected to exist prior to reduction by
ascorbate. All other residues used potential parameters from the CHARMM27 force field.
The PHM system was then solvated in a 120 Å3 water box using the TIP3P water model
to which Na+ and Cl- counter-ions were added to a concentration of 100 mM. NAMD was then
used to equilibrate the system. All PHM non-backbone atoms were fixed and the system was
energy minimized for 10,000 steps followed by a minimization of all atoms for 10,000 steps.
The system was then heated with Cα constrained for 10 ps in the NVT ensemble (T=310.15 K),
volume equilibrated in the NPT ensemble with Cα constrained, and free dynamics performed in
the NPT ensemble (P=1 atm, T=310.15 K) for 2.4 ns (Figure 5.4). Two separate systems were
then created using the equilibrated PHM structure to probe for both ascorbate (ASC) and
mimosine (MIM) binding sites. The desired probe (ASC or MIM) was added to the solution
surrounding the equilibrated PHM structure to a concentration of ~10 mM. A new set of
counter-ions was added to a concentration of 100mM.
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All PHM atoms were fixed and the system was energy minimized for 3,000 steps and

dynamics run for 200 ps on the water and counter-ions. The ASC or MIM molecules were then
released and, with PHM still fixed, the system was minimized for 5,000 steps and dynamics was
performed for 500 ps. These steps were performed in the NVT ensemble (T=310.15 K). All
atoms were then released from constraints, the system minimized for 3,000 steps, and free
dynamics in the NPT ensemble (P=1 atm, T=310.15 K) run for 80 ns. All simulations described
utilized periodic boundary conditions and the Particle Mesh Ewald (PME) method to calculate
electrostatic forces without cutoff[20]. Van der Waals interactions were calculated with a cutoff
of 12 Å and a switching distance of 10 Å. Bonded forces, short range non-bonded forces (within
the cutoff), and long range electrostatics (outside the cutoff) were evaluated every femtosecond
during the initial equilibration of the PHM structure. For the binding simulation, a multiple
time-stepping algorithm[21, 22] was utilized with a 1 fs step for bonded force evaluation, 2 fs for
short range non-bonded forces (within the cutoff), and 4 fs for long range electrostatics (outside
the cutoff). Langevin dynamics was used to control the temperature using a damping coefficient
of 5 ps-1 with hydrogen atoms not coupled to the heat bath. Pressure was regulated via the hybrid
Nose-Hoover[23] Langevin[24] piston method using a piston oscillation period of 100 fs and a
damping time scale of 50 fs.

Steered Molecular Dynamics
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Upon binding of ascorbate or mimosine in their respective simulations, ten starting

structures from each simulation were collected for multiple steering molecular dynamics
simulations. External steering forces were then applied to pull the ligand, ASC or MIM, out of
its binding site. The ligands were pulled under constant velocity in directions predetermined
through visualization, one pull per each of the 20 collected starting structures (Figure 5.5).
Bonded forces, short range non-bonded forces (within the cutoff), and long range
electrostatics (outside the cutoff) were evaluated every femtosecond for all steered molecular
dynamics simulations. The pulling velocity was set at 0.00005 Å per time step (1 fs). A spring
constant of 7 kcal/mol/Å2 was used to constrain the ligand. This constraint is large enough to
allow for the use of the stiff spring approximation[25, 26]. For all pulling simulations, the
pulling force was applied to the atoms indicated in Figure 5.6. The force was only applied along
the pulling direction during the simulation. The ligands were free from constraint in the plane
perpendicular to the pulling vector. Trajectories were saved every 0.1 ps, and steering forces
recorded every 10 fs.
Analysis of Trajectories
The methods used to construct the potential of mean force (PMF) from the steered
molecular dynamics simulations were all based on Jarzynski’s equality and were independent of
the friction coefficient [27]. The reaction coordinate was the increasing distance between the
ligand and the binding site during the pulling simulation. Because drifting of the protein would
change the distance between the ligand and the binding site throughout the simulation, several
atoms on the side opposite of the binding site were fixed on the protein (Figure 5.7).
Sp ecifically, these were the Cα of LYS3 3 6 and ASN3 3 7 . The u se of 1 0 trajecto ries for both
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ASC and MIM are sufficient as fewer slower pulling trajectories have been demonstrated to yield

more accurate PMF values[25, 26]. The 50 Å/ns pulling velocity is sufficiently slow to produce
accurate PMF values from the number of trajectories used here.
The pulling force was calculated using the following equation:
(1)
where F is the pulling force, t is time, k is the spring constant of the constraint, v is the pulling
velocity, n is the pulling direction normal, and r(t) and r0 are the positions of the ligand at time t
and t0.
Work was calculated by integrating the force over the distance pulled from the pulling
trajectories:
(2)
The PMF, or free-energy difference, was derived from work W utilizing Jarzynski’s
equality as follows[26, 28]:

(3)

where R is the universal gas constant and T is the absolute temperature. Previous work by the
Schulten group has demonstrated that work distribution from Langevin dynamics satisfies a
Gaussian distribution and can be expressed as a second-order cumulant expansion[26]:

(4)
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is the average work from all trajectories and σW is the standard deviation of the work

where

distribution.
Results
Ascorbate binding simulations
The simulation for the ascorbate binding experiment reveals the probe diffusing though
the aqueous solution around PHM. Some of the ligands search the surface of PHM and again
diffuse.

Some ascorbate molecules in the simulation search the surface and bind to it

temporarily. One ascorbate molecule in the simulation, however, binds and remains bound for
15 ns. The criteria for determining the legitimacy of a binding site included two important
guidelines. The binding site must be a depressed, hydrophobic pocket and not simply hydrogen
bonding interactions on the surface of PHM. The binding should last on the order of >10 ns to
ensure sufficient interaction strength. The ascorbate simulation was carried out for 79 ns and
revealed only one potential binding site for ascorbate (Figure 5.8).
The binding site for ascorbate is a depression on the PHM surface that includes residues
important for strong hydrogen bonding. These residues include ASP61, GLN198, and LYS152.
A frame from the trajectory during the “ascorbate on” portion of the simulation is rendered
below (Figure 5.9).
As a means of measuring the amount of time the particular binding ascorbate ligand spent
bound to the enzyme, hydrogen bonding was monitored between the ascorbate ligand and the
surface of PHM. The data indicates that ascorbate bound to PHM for ~15 ns before diffusing.
This meets our criteria for legitimate binding and is depicted in Figure 5.10.
Mimosine binding simulations
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The simulation for the mimosine binding experiment was performed in the same manner
as that of the ascorbate binding experiment. Mimosine diffused freely throughout the solvent

during the simulation. The mimosine simulation was carried out for ~82 ns, and only one
potential binding site for mimosine was identified (Figure 5.11).
The binding site for mimosine is a depression on the PHM surface much like that of
ascorbat and includes residues important for strong hydrogen bonding. The binding site residues
include ASN45, ARG67, ARG100, and LYS98.

A frame from the trajectory during the

mimosine bound portion of the simulation is rendered in Figure 5.12.
In order to determine the amount of time mimosine was bound to PHM during the
simulations, the hydrogen bonding between the bound ligand and the binding site was
investigated. Figure 5.13 illustrates that mimosine seemed to bind longer than ascorbate perhaps
suggesting a stronger interaction which would be consistent with what has been observed
experimentally.
Because ascorbate and mimosine were shown to bind in close proximity but different
binding pockets, the particle mesh Ewald electrostatic potential of PHM was calculated for the
“on” and “off” states of both ligands. This illustrates that the electrostatic effects of mimosine
binding would indeed affect the binding pocket of ascorbate. Thus, the seemingly competitive
experimental data may not rule out slightly differing binding sites within a few angstroms of one
another (Figures 5.14 & 5.15).
Steered Molecular Dynamics
The SMD simulations for both ascorbate and mimosine yielded force data that fluctuate
between positive and negative values (Figure 5.16). This indicates that the thermal fluctuation of
the ligand (ASC or MIM) is larger than the perturbation from the pulling. This shows that the
127

Chapter Five: Computational Elucidation of Reductant
Binding Sites in PAM

process by which the ligand unbinds is near equilibrium. No conformational changes were seen

during the unbinding process with mild peaks in the force graph relating only to the breaking of
hydrogen bonds.
The unbinding of the two ligands, ascorbate and mimosine, are nonequilibrium processes.
The external work was sampled from repeated trajectories in order to calculate the potential of
mean force using the Jarzynski equality (Figure 5.17). Jarzynski’s equality cannot be used
directly unless the deviation of work distribution

≤ 4kT which is generally not true for

biological systems of the size simulated here[19]. Because standard deviation will grow as the
ligand is pulled further from the binding site, the free energy estimated from the Jarzynski
equality is dominated by smaller values of work.

The cumulant expansion method was

developed to solve this problem[25, 26] (Figure 5.18). Utilizing the cumulant expansion method
improves the statistics of work distribution caused by having such limited sampling when
calculating the PMF.
Discussion
The simulations performed in an attempt to elucidate the binding site for ascorbate, the
reductant of PAM, have led to the discovery of a possible binding site. The successful
elucidation of a binding site will help eliminate some of the proposed mechanisms and help
determine where electron transfer occurs prior to the reduction of CuM. The mimosine
simulation was used as a control in that an ascorbate binding site would either accommodate
mimosine or a mimosine binding site would be very nearby. This proved to be the case in the
proposed ascorbate binding site. Mimosine binds within a few angstroms of ascorbate.
Another method used as a way of verifying the proposed binding site was the calculation
of the free energy of binding. While the calculated free energy for mimosine can be directly
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compared with the experimental KI value (4 µM) as no chemistry is occurring, that of ascorbate
is a KM (223 µM) and cannot be compared directly but is a good estimate. Using the equations
for Gibbs free energy:

(5)
where K is the Kd or KM for mimosine and ascorbate, respectively, calculated from the PMF
values for free energy simulated. The calculated PMF values for ascorbate yields a theoretical
KM of 200 µM. This is sufficiently close to justify consideration of the proposed binding site as
valid. The theoretical KI of mimosine from the simulation results in a value of 1 µM which is
also consistent with the experimental data within the accepted error for this type of free energy
calculation.
While initial results are convincing, more work is needed to experimentally verify these
initial findings. Mutants targeting the proposed binding site should be made and the effects of
these mutations tested on reduction of PAM by ascorbate. A quicker method may be to perform
in silico docking of a library of commercially available compounds. Hits for binding in the
proposed binding site should be tested as competitive inhibitors against the reduction of PAM by
ascorbate.
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Figure 5.1. Peptidylglycine α-amidating monooxygenase reaction.

Note, Asc represents

ascorbate, deAsc represents semidehydroascorbate, PAM is peptidylglycine a-amidating
monooxygenase, PHM is peptidylglycine α-hydroxylating monooxygenase, and PAL is
peptidylgycine amidoglycolate lyase.
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Figure 5.2. States A and B in which state A is the starting structure and state B is the final state
post SMD simulation. Water and ions omitted for clarity.

134

Chapter Five: Computational Elucidation of Reductant
Binding Sites in PAM

Figure 5.3.

Methyl-capped CuH and CuM domains in the PHM crystal structure prior to

geometry optimization.

135

Chapter Five: Computational Elucidation of Reductant
Binding Sites in PAM

Figure 5.4. PHM crystal structure “soaked” with ascorbate. Note, water and ions not shown for
clarity.
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Figure 5.5. Illustration of the PHM secondary structure with bound ascorbate and the spring as
the force vector applied during the steering molecular dynamics simulations.
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k

k

Figure 5.6. Ascorbate and mimosine used to probe for a reductant binding site on PHM and the
carbon atoms in which the force was applied during the steered molecular dynamics simulation.
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Figure 5.7. PHM secondary structure with bound ascorbate and the fixed L336 and N337.
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Figure 5.8. Ascorbate bound to the surface of PHM.
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Figure 5.9. Ascorbate in the proposed binding pocket with hydrogen bonding illustrated as blue
or red dashed lines.
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Figure 5.10. Hydrogen bonding between ascorbate and the proposed PHM binding site.
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Figure 5.11. Mimosine bound to the surface of PHM.
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Figure 5.12. Mimosine in the proposed binding pocket with hydrogen bonding illustrated as
blue dashed lines.
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Figure 5.13. Hydrogen bonding between mimosine and the proposed PHM binding site.
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Figure 5.14. PME electrostatic potential of PHM with “off” and “on” ascorbate.
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Figure 5.15. PME electrostatic potential of PHM with “off” and “on” mimosine.
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Figure 5.16. Force vs extension for both ascorbate and mimosine over a 5 Å reaction
coordinate.

148

Chapter Five: Computational Elucidation of Reductant
Binding Sites in PAM

Figure 5.17. Work vs extension for ascorbate and mimosine unbinding.
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Figure 5.18. Potential of mean force vs extension for ascorbate and mimosine unbinding.
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Appending A
PCGAMESS Geometry Optimization Settings
File 1. L3Cu(I)-thiophenolate geometry optimization (truncated)

! Geometry optimize the CuM cluster with thiophenolate anion coordinated
! (froze the carbons of the methyl caps to simulated the protein backbone)
! lanl2dz basis set
!
! Jon Belof/Edward W. Lowe
! Department of Chemistry
! University of South Florida
!
$CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE MAXIT=200 ECP=READ $END
$SYSTEM TIMLIM=9999999999 MWORDS=70 $END
$STATPT NSTEP=1000 IFREEZ(1)=10,11,12,13,14,15,16,17,18 $END
$DFT DFTTYP=B3LYP $END
$GUESS GUESS=HUCKEL $END
$ECP
CU-ECP GEN 10 2
3
----- d potential -----10.0000000
1 511.9951763
-72.5548282
2 93.2801074
-12.7450231
2 23.2206669
4
----- s-d potential ----3.0000000
0 173.1180854
23.8351825
1 185.2419886
473.8930488
2 73.1517847
157.6345823
2 14.6884157
4
----- p-d potential ----5.0000000
0 100.7191369
6.4990936
1 130.8345665
351.4605395
2 53.8683720
85.5016036
2 14.0989469
S-ECP GEN 10 2
5
----- d potential -----10.0000000
1 532.6685222
-85.3593846
2 108.1342248
-30.4513290
2 24.5697664
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-10.3745886
2
7.3702438
-0.9899295
2
2.3712569
5
----- s-d potential ----3.0000000
0 106.3176781
10.6284036
1 100.8245833
223.6360469
2 53.5858472
93.6460845
2 15.3706332
28.7609065
2
3.1778402
6
----- p-d potential ----5.0000000
0 101.9709185
6.0969842
1 93.2808973
285.4425500
2 65.1431772
147.1448413
2 24.6347440
53.6569778
2
7.8120535
8.9249559
2
2.3112730
$END
$DATA
File 2. L3Cu(I)-H2O geometry optimization (truncated)

! Geopt of CuM cluster with frozen methyl caps and water coordinated lanl2dz
! Edward W. Lowe Jr
! Merkler Research Group
! Department of Chemistry
! University of South Florida
$CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=+1 MULT=1 UNITS=ANGS
$END
$CONTRL INTTYP=HONDO ICUT=10 MAXIT=1000 ECP=READ $END
$SYSTEM TIMLIM=9999999999 MWORDS=70 $END
$SMP CSMTX=.T. $END
$P2P P2P=.T. DLB=.T. $END
$SCF DIRSCF=.TRUE. FDIFF=.FALSE. SOSCF=.FALSE. $END
$SCF DIIS=.TRUE. DAMP=.T. ETHRSH=2.0 $END
$STATPT NSTEP=1000 OPTTOL=0.00001 HESS=CALC $END
$STATPT IFREEZ(1)=1,2,3,19,20,21,37,38,39 $END
$DFT DFTTYP=B3LYP $END
$GUESS GUESS=HUCKEL $END
$ECP
CU-ECP GEN 10 2
152

3

----- d potential -----10.0000000
1 511.9951763
-72.5548282
2 93.2801074
-12.7450231
2 23.2206669
4
----- s-d potential ----3.0000000
0 173.1180854
23.8351825
1 185.2419886
473.8930488
2 73.1517847
157.6345823
2 14.6884157
4
----- p-d potential ----5.0000000
0 100.7191369
6.4990936
1 130.8345665
351.4605395
2 53.8683720
85.5016036
2 14.0989469
S-ECP GEN 10 2
5
----- d potential -----10.0000000
1 532.6685222
-85.3593846
2 108.1342248
-30.4513290
2 24.5697664
-10.3745886
2
7.3702438
-0.9899295
2
2.3712569
5
----- s-d potential ----3.0000000
0 106.3176781
10.6284036
1 100.8245833
223.6360469
2 53.5858472
93.6460845
2 15.3706332
28.7609065
2
3.1778402
6
----- p-d potential ----5.0000000
0 101.9709185
6.0969842
1 93.2808973
285.4425500
2 65.1431772
147.1448413
2 24.6347440
53.6569778
2
7.8120535
8.9249559
2
2.3112730
$END
$DATA
File 3. L3Cu(I) geometry optimization (truncated)
! Geometry optimize the CuM cluster with no water coordinated
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! (froze the carbons of the methyl caps to simulated the protein backbone)
! lanl2dz
! Jon Belof/Edward W. Lowe
! Department of Chemistry
! University of South Florida
!
$CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=1 MAXIT=200 ECP=READ
$END
$SYSTEM TIMLIM=9999999999 MWORDS=235 $END
$STATPT NSTEP=200 IFREEZ(1)=10,11,12,13,14,15,16,17,18 $END
$DFT DFTTYP=B3LYP $END
$GUESS GUESS=HUCKEL $END
$ECP
CU-ECP GEN 10 2
3
----- d potential -----10.0000000
1 511.9951763
-72.5548282
2 93.2801074
-12.7450231
2 23.2206669
4
----- s-d potential ----3.0000000
0 173.1180854
23.8351825
1 185.2419886
473.8930488
2 73.1517847
157.6345823
2 14.6884157
4
----- p-d potential ----5.0000000
0 100.7191369
6.4990936
1 130.8345665
351.4605395
2 53.8683720
85.5016036
2 14.0989469
S-ECP GEN 10 2
5
----- d potential -----10.0000000
1 532.6685222
-85.3593846
2 108.1342248
-30.4513290
2 24.5697664
-10.3745886
2
7.3702438
-0.9899295
2
2.3712569
5
----- s-d potential ----3.0000000
0 106.3176781
10.6284036
1 100.8245833
223.6360469
2 53.5858472
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93.6460845
2 15.3706332
28.7609065
2
3.1778402
6
----- p-d potential ----5.0000000
0 101.9709185
6.0969842
1 93.2808973
285.4425500
2 65.1431772
147.1448413
2 24.6347440
53.6569778
2
7.8120535
8.9249559
2
2.3112730
$END
$DATA
File 4. L3Cu(II) geometry optimization of CuM for NAMD parameterization

!Optimization of CuM for the ascorbate binding site probe using NAMD
!Edward W. Lowe
!Merkler Research Group
!University of South Florida
!05/04/07
$CONTRL SCFTYP=UHF RUNTYP=OPTIMIZE ICHARG=+2 MULT=2 $END
$CONTRL INTTYP=HONDO ICUT=10 MAXIT=75 ECP=SBK $END
$SYSTEM KDIAG=0 TIMLIM=999999999 MWORDS=23 $END
$SMP CSMTX=.T. $END
$P2P P2P=.T. DLB=.T. $END
$TRANS AOINTS=DIST $END
$SCF DIRSCF=.T. FDIFF=.F. SOSCF=.F. DIIS=.T. ETHRSH=2.0 $END
$STATPT NSTEP=1000 HESS=CALC $END
$STATPT IFREEZ(1)=13,14,15 $END
$STATPT IFREEZ(2)=49,50,51 $END
$STATPT IFREEZ(3)=76,77,78 $END
$DFT DFTTYP=B3LYP $END
$GUESS GUESS=HUCKEL $END
$BASIS GBASIS=SBK $END
$DATA
CuM with water for thiol paper geopt
C1
H 1.0 -1.40800 -6.66500 0.02200
N 7.0 -0.45700 -3.88900 0.20500
H 1.0 -1.36400 -3.51400 0.01000
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C 6.0
C 6.0
H 1.0
H 1.0
N 7.0
C 6.0
H 1.0
C 6.0
H 1.0
H 1.0
N 7.0
H 1.0
C 6.0
C 6.0
H 1.0
H 1.0
N 7.0
C 6.0
H 1.0
C 6.0
H 1.0
H 1.0
C 6.0
H 1.0
H 1.0
C 6.0
H 1.0
H 1.0
S 16.0
C 6.0
H 1.0
H 1.0
H 1.0
Cu 29.0
$END
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-0.18600 -5.13500 0.72900
-1.21300 -6.20000 0.90400
-2.05800 -5.78700 1.49600
-0.78100 -7.03400 1.50000
1.71100 -3.96100 0.53200
1.16200 -5.16900 0.92700
1.78700 -5.97500 1.29300
0.71100 -3.21300 0.11000
0.79400 -2.18800 -0.26100
2.80000 -3.66700 -5.08200
5.63800 -3.10800 -3.17700
6.42700 -3.01200 -3.78500
4.32400 -3.25600 -3.56400
3.86900 -3.38000 -4.98500
4.47300 -4.16500 -5.49000
4.06600 -2.42700 -5.52400
4.45300 -3.06700 -1.32800
3.59600 -3.23700 -2.41500
2.53000 -3.36200 -2.27000
5.66700 -2.99600 -1.83500
6.58300 -2.85800 -1.25400
4.93600 -7.63500 -1.24100
4.39500 -7.14200 -0.41800
3.73600 -6.41300 -0.94600
3.74900 -7.66600 0.32100
5.53200 -6.39500 0.26700
6.24300 -7.11300 0.72800
6.09500 -5.80000 -0.48500
4.86300 -5.30900 1.55000
6.42100 -4.66400 2.29100
6.20300 -3.96700 3.12800
7.04600 -5.49200 2.69000
7.02400 -4.11300 1.53700
3.77600 -3.54100 0.63000

File 5. L3Cu(II) geometry optimization of CuH for NAMD parameterization
!Optimization of CuH for the ascorbate binding site probe using NAMD
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!Edward W. Lowe
!Merkler Research Group
!University of South Florida
!05/04/07
$CONTRL SCFTYP=UHF RUNTYP=OPTIMIZE ICHARG=+2 MULT=2 $END
$CONTRL INTTYP=HONDO ICUT=10 MAXIT=75 ECP=SBK $END
$SYSTEM KDIAG=0 TIMLIM=999999999 MWORDS=235 AOINTS=DIST $END
$SMP CSMTX=.T. $END
$P2P P2P=.T. DLB=.T. $END
$SCF DIRSCF=.T. FDIFF=.F. SOSCF=.F. DIIS=.T. ETHRSH=2.0 $END
$STATPT NSTEP=1000 HESS=CALC $END
$STATPT IFREEZ(1)=13,14,15 $END
$STATPT IFREEZ(2)=49,50,51 $END
$STATPT IFREEZ(3)=76,77,78 $END
$DFT DFTTYP=B3LYP $END
$BASIS GBASIS=SBK $END
$GUESS GUESS=HUCKEL $END
$DATA
CuH rxn center geopt
C1
H 1.0 -6.119 6.698 -0.238
N 7.0 -5.674 4.283 -3.250
H 1.0 -5.965 3.920 -4.135
C 6.0 -5.797 5.589 -2.834
H 1.0 -6.243 6.369 -3.435
N 7.0 -4.798 4.407 -1.231
C 6.0 -5.252 5.651 -1.592
C 6.0 -5.067 3.616 -2.254
H 1.0 -4.824 2.551 -2.295
C 6.0 -5.148 6.819 -0.667
H 1.0 -4.962 7.729 -1.277
H 1.0 -4.279 6.702 0.014
H 1.0 -5.795 4.086 2.649
N 7.0 -2.530 2.247 3.704
H 1.0 -1.878 1.910 4.382
C 6.0 -3.893 2.373 3.885
H 1.0 -4.401 2.121 4.805
N 7.0 -3.372 2.999 1.816
C 6.0 -4.395 2.839 2.714
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C 6.0
H 1.0
C 6.0
H 1.0
H 1.0
H 1.0
N 7.0
H 1.0
C 6.0
H 1.0
N 7.0
C 6.0
C 6.0
H 1.0
C 6.0
H 1.0
H 1.0
Cu 29.0
$END

-2.272
-1.273
-5.816
-6.449
-5.927
-2.117
-0.484
0.160
-0.652
-0.097
-2.017
-1.598
-1.325
-1.416
-2.160
-1.639
-3.237
-3.637

2.635
2.641
3.154
2.318
3.185
7.001
6.682
7.116
7.001
7.779
5.319
6.155
5.669
5.195
6.049
5.214
5.784
3.998
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2.446
2.003
2.352
2.719
1.248
2.768
-0.781
-1.410
0.549
1.053
0.023
1.030
-1.046
-2.026
2.414
2.931
2.373
0.110

File 6. Geometry optimization of ascorbate for NAMD parameterization
$CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=0 MULT=1 COORD=ZMT
NZVAR=54 $END
$CONTRL MAXIT=75 $END
$SYSTEM TIMLIM=999999999 MWORDS=235 $END
$SCF DIRSCF=.TRUE. $END
$STATPT NSTEP=1000 $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$ELPOT IEPOT=1 WHERE=PDC $END
$PDC PTSEL=CONNOLLY CONSTR=CHARGE $END
$FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END
$ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,3,1,5,4,1,6,2,1,7,4,1,8,7,1,9,5,
1,10,1,1,11,7,1,12,11,1,13,4,1,14,7,1,15,11,1,16,11,
1,17,12,1,18,8,1,19,10,1,20,9,
2,3,2,1,2,4,3,2,2,5,4,3,2,6,2,3,2,7,4,3,2,8,7,4,
2,9,5,4,2,10,1,2,2,11,7,4,2,12,11,7,2,13,4,3,2,14,7,4,
2,15,11,7,2,16,11,7,2,17,12,11,2,18,8,7,2,19,10,1,2,20,7,5,
3,4,3,2,1,3,5,4,3,2,3,6,2,3,4,3,7,4,3,2,3,8,7,4,3,
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3,9,5,4,3,3,10,1,2,3,3,11,7,4,3,3,12,11,7,4,3,13,4,3,2,
3,14,7,4,3,3,15,11,7,4,3,16,11,7,4,3,17,12,11,7,3,18,8,7,4,
3,19,10,1,2,3,20,9,5,4
$END
$DATA
ascorbate toppar
C1
C
O
1 1.3993695
C
2 1.4911748 1
C
3 1.5083526 2
C
4 1.3447000 3
C
3 1.5288325 2
C
6 1.5314014 3
O
7 1.4620625 6
O
6 1.4454707 3
O
1 1.2312353 2
O
5 1.3768209 4
O
4 1.3704297 3
H
3 1.0945449 2
H
6 1.0991831 3
H
7 1.0937666 6
H
7 1.0980365 6
H
8 0.9758375 7
H
9 0.9819455 6
H 11 0.9808199 5
H 12 0.9799619 4
$END
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109.3353707
102.8105937 1 0.4558029 0
110.2718397 2 -0.5401568 0
108.6056231 1 -123.6554732 0
113.7297864 2 172.2854080 0
103.6177438 3 171.2245510 0
105.7709296 2 -68.4700166 0
124.4287108 3 -179.7704008 0
126.8178161 3 179.5237568 0
119.9144041 2 178.6049028 0
106.7457350 1 119.0405695 0
108.6614051 2 50.6657410 0
111.7872871 3 -68.8319724 0
110.1003640 3 52.5684184 0
111.3198901 6 -171.5451546 0
107.0046583 3 -170.4584470 0
109.9007971 4 -178.8505208 0
111.6479499 3 -177.6398852 0

File 7. Geometry optimization of mimosine for NAMD parameterization
$CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE ICHARG=-1 MULT=1 COORD=ZMT
NZVAR=63 $END
$CONTRL MAXIT=75 $END
$SYSTEM TIMLIM=999999999 MWORDS=235 $END
$SCF DIRSCF=.TRUE. $END
$STATPT NSTEP=1000 $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$ELPOT IEPOT=1 WHERE=PDC $END
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$PDC PTSEL=CONNOLLY CONSTR=CHARGE $END
$FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END
$DATA
mimosine toppar
C1
c
c 1 cc2
c 2 cc3
1 ccc3
n 3 nc4
2 ncc4
1 dih4
c 4 cn5
3 cnc5
2 dih5
c 5 cc6
4 ccn6
3 dih6
o 2 oc7
3 occ7
4 dih7
c 4 cn8
3 cnc8
2 dih8
c 8 cc9
4 ccn9
3 dih9
n 9 nc10
8 ncc10
4 dih10
o 1 oc11
2 occ11
3 dih11
c 9 cc12
8 ccc12
4 dih12
o 12 oc13
9 occ13
8 dih13
o 12 oc14
9 occ14
8 dih14
h 3 hc15
2 hcc15
1 dih15
h 5 hc16
4 hcn16
3 dih16
h 6 hc17
5 hcc17
4 dih17
h 7 ho18
2 hoc18
3 dih18
h 8 hc19
4 hcn19
3 dih19
h 8 hc20
4 hcn20
3 dih20
h 9 hc21
8 hcc21
4 dih21
h 10 hn22
9 hnc22
8 dih22
h 10 hn23
9 hnc23
8 dih23
cc2
cc3
ccc3
nc4
ncc4
dih4
cn5
cnc5
dih5
cc6

1.409701
1.399166
118.654
1.368604
121.037
-0.201
1.367139
120.411
0.620
1.395360
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ccn6
dih6
oc7
occ7
dih7
cn8
cnc8
dih8
cc9
ccn9
dih9
nc10
ncc10
dih10
oc11
occ11
dih11
cc12
ccc12
dih12
oc13
occ13
dih13
oc14
occ14
dih14
hc15
hcc15
dih15
hc16
hcn16
dih16
hc17
hcc17
dih17
ho18
hoc18
dih18
hc19
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120.605
-0.665
1.380548
118.403
179.856
1.472220
119.482
179.991
1.541563
111.386
71.975
1.463633
109.893
-177.868
1.350598
121.154
179.946
1.507657
110.483
60.722
1.225477
120.220
73.235
1.352379
119.610
-96.438
1.083728
118.813
179.605
0.983454
120.565
179.918
1.083065
119.985
-179.661
0.990257
109.377
-179.940
1.114040
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hcn19
dih19
hc20
hcn20
dih20
hc21
hcc21
dih21
hn22
hnc22
dih22
hn23
hnc23
dih23
$END
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110.876
-166.298
1.112321
109.145
-49.392
1.113838
109.120
-58.779
1.046531
108.316
177.274
1.046012
108.372
62.789

File 8. General input for all PBA geometry optimizations
$CONTRL ICHARG=-1 MULT=1 RUNTYP=OPTIMIZE SCFTYP=RHF COORD=CART
$END
$CONTROL UNITS=ANGS MAXIT=200 $END
$DFT DFTTYP=B3LYP METHOD=GRID $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$STATPT METHOD=QA NSTEP=1000 OPTTOL=0.0001 HESS=CALC $END
$GUESS GUESS=HUCKEL $END
$SYSTEM MWORDS=200 $END
$P2P P2P=.T. DLB=.T. $END
$DATA
pba geopt
C1
C 6.0 -1.21290 1.62180 0.02210
C 6.0 -1.98910 2.79560 -0.04280
C 6.0 -3.38860 2.68230 -0.12420
C 6.0 -4.00030 1.42460 -0.11890
C 6.0 -3.22200 0.26740 -0.04100
C 6.0 -1.82980 0.36600 0.02630
H 1.0 -0.13300 1.66350 0.04760
C 6.0 -1.37430 4.14610 -0.05840
H 1.0 -3.95040 3.48720 -0.17960
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H 1.0
H 1.0
H 1.0
C 6.0
C 6.0
C 6.0
O 8.0
O 8.0
H 1.0
H 1.0
H 1.0
H 1.0
$END

-5.07890
-3.65420
-1.28160
0.01850
0.57530
1.76220
1.58680
2.97600
-1.93810
0.60170
-0.15140
0.89630
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1.34760 -0.17620
-0.61520 -0.03880
-0.44850 0.07100
4.41530 0.37530
5.65830 0.28230
5.62260 -0.63100
5.73260 -1.96700
5.27760 -0.14560
4.91010 -0.32520
3.62470 0.83730
6.40800 -0.10090
5.99040 1.29280

File 9. General input for PBA single point energy calculations
$CONTRL COORD=CART ICHARG=-1 MAXIT=200 MPLEVL=2
MULT=1 RUNTYP=ENERGY SCFTYP=RHF UNITS=ANGS
$END
$BASIS DIFFS=.true. GBASIS=N311 NDFUNC=2
NFFUNC=1 NGAUSS=6 NPFUNC=1 POLAR=HONDO7
$END
$SCF DAMP=.false. DEM=.false. DIIS=.false.
DIRSCF=.true. EXTRAP=.true. RSTRCT=.false.
SHIFT=.false. SOSCF=.true.
$END
$STATPT METHOD=QA NSTEP=1000 OPTTOL=0.001
$END
$P2P P2P=.T. DLB=.T. $END
$FORCE TEMP=0
$END
$GUESS
GUESS=HUCKEL
$END
$SYSTEM
MWORDS=100
$END
$DATA
high level spe for RSE
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C1
C 6.0
C 6.0
C 6.0
C 6.0
C 6.0
C 6.0
H 1.0
C 6.0
H 1.0
H 1.0
H 1.0
H 1.0
C 6.0
C 6.0
C 6.0
O 8.0
O 8.0
H 1.0
H 1.0
H 1.0
H 1.0
$END
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1.64210
1.39220
2.49530
3.79150
4.02160
2.93620
0.81830
0.03280
2.33020
4.61830
5.02340
3.09770
-1.07700
-2.44780
-3.55620
-4.58990
-3.31650
-0.03150
-1.05380
-2.51460
-2.69920

1.04520 0.01360
-0.33140 0.06250
-1.18880 0.02550
-0.69980 -0.04000
0.66700 -0.07370
1.53430 -0.04800
1.73130 0.00850
-0.89950 0.14130
-2.25030 0.05320
-1.38580 -0.06430
1.05040 -0.12550
2.59580 -0.08560
-0.24630 0.47900
-0.83830 0.54640
0.11790 0.02940
-0.44840 -0.40270
1.35010 0.14560
-1.94980 -0.09300
0.79980 0.72080
-1.77740 0.01190
-1.04500 1.58790

File 10. General input for PBA radical geometry optimizations (truncated)
$CONTRL ICHARG=-1 MULT=2 RUNTYP=OPTIMIZE SCFTYP=UHF COORD=CART
$END
$CONTROL UNITS=ANGS MAXIT=200 $END
$DFT DFTTYP=B3LYP METHOD=GRID $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$STATPT METHOD=QA NSTEP=1000 OPTTOL=0.0001 HESS=CALC $END
$GUESS GUESS=HUCKEL $END
$SYSTEM MWORDS=200 $END
$P2P P2P=.T. DLB=.T. $END
$DATA
pba radical geopt
File 11. General input for PBA radical single point energy calculations (truncated)
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$CONTROL RUNTYP=ENERGY COORD=CART ICHARG=-1 MULT=2 $END
$CONTROL MAXIT=200 MPLEVL=2 SCFTYP=UHF UNITS=ANGS $END
$BASIS GBASIS=N311 NDFUNC=2 NFFUNC=1 NGAUSS=6 NPFUNC=1 $END
$STATPT NSTEP=1000 $END
$GUESS GUESS=HUCKEL $END
$SYSTEM MWORDS=200 $END
$DATA
high level spe for RSE

File 12. General input for cinnamate analog geometry optimizations (truncated)
$CONTRL ICHARG=-1 MULT=1 RUNTYP=OPTIMIZE SCFTYP=RHF COORD=CART
$END
$CONTRL UNITS=ANGS MAXIT=10000 $END
$SYSTEM KDIAG=0 TIMLIM=999999999 AOINTS=DIST $END
$SMP CSMTX=.T. $END
$P2P P2P=.T. DLB=.T. $END
$SCF DIRSCF=.T. FDIFF=.F. SOSCF=.F. DIIS=.T. ETHRSH=2.0 $END
$DFT DFTTYP=B3LYP METHOD=GRID $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$STATPT METHOD=QA NSTEP=1000 OPTTOL=0.0001 HESS=CALC $END
$GUESS GUESS=HUCKEL $END
$SYSTEM MWORDS=200 $END
$P2P P2P=.T. DLB=.T. $END
$DATA
Appendix B
PCGAMESS Hessian Calculation Input Files
File 13. Hessian calculation for L3Cu(I) CuM for NAMD parameterization (truncated)
$CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=+1 MULT=1 COORD=ZMT
NZVAR=105 $END
$CONTRL MAXIT=100 ECP=SBK $END
$SYSTEM TIMLIM=9999999999 MWORDS=200 $END
$SCF DIRSCF=.TRUE. $END
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$STATPT NSTEP=1000 HESS=CALC $END
$GUESS GUESS=HUCKEL $END
$BASIS GBASIS=SBK $END
$ELPOT IEPOT=1 WHERE=PDC $END
$PDC PTSEL=CONNOLLY CONSTR=CHARGE $END
$FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END
$ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,2,1,5,1,1,6,5,1,7,5,1,8,2,1,9,4,1,10,9,
1,11,8,1,12,11,1,13,8,1,14,13,1,15,14,1,16,14,1,17,13,1,18,17,1,19,17,
1,20,14,1,21,16,1,22,21,1,23,20,1,24,23,1,25,24,1,26,25,1,27,26,1,28,26,
1,29,26,1,30,29,1,31,29,1,32,29,1,33,32,1,34,33,1,35,33,1,36,33,1,37,20,
2,3,2,1,2,4,2,1,2,5,1,2,2,6,5,1,2,7,5,1,2,8,2,1,2,9,4,2,2,10,9,4,2,11,8,2,
2,12,11,8,2,13,8,2,2,14,13,8,2,15,14,13,2,16,14,13,2,17,13,8,2,18,17,13,
2,19,17,13,2,20,14,13,2,21,16,14,2,22,21,16,2,23,20,14,2,24,23,20,2,25,24,23,
2,26,25,24,2,27,26,25,2,28,26,25,2,29,26,25,2,30,29,26,2,31,29,26,2,32,29,26,
2,33,32,29,2,34,33,32,2,35,33,32,2,36,33,32,2,37,20,14,3,4,2,1,3,3,5,1,2,3,3,6,5,1,2,3,7,5,1,2,3,8,
2,1,3,3,9,4,2,1,3,10,9,4,2,3,11,8,2,1,3,12,11,8,2,3,13,8,2,1,3,14,13,8,2,3,15,14,13,8,3,16,14,13,8,
3,17,13,8,2,3,18,17,13,8,3,19,17,13,8,3,20,14,13,8,3,21,16,14,13,3,22,21,16,14,3,23,20,14,13,3,2
4,23,20,14,3,25,24,23,20,3,26,25,24,23,3,27,26,25,24,3,28,26,25,24,3,29,26,25,24,3,30,29,26,25,
3,31,29,26,25,3,32,29,26,25,3,33,32,29,26,3,34,33,32,29,3,35,33,32,29,3,36,33,32,29,3,37,20,14,
13,
$END
$DATA
File 14. Hessian calculation for L3Cu(II) CuM for NAMD parameterization (truncated)
$CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=+2 MULT=2 COORD=ZMT
NZVAR=105 $END
$CONTRL MAXIT=100 ECP=SBK $END
$SYSTEM TIMLIM=9999999999 MWORDS=200 $END
$SCF DIRSCF=.TRUE. $END
$STATPT NSTEP=1000 HESS=CALC $END
$GUESS GUESS=HUCKEL $END
$BASIS GBASIS=SBK $END
$ELPOT IEPOT=1 WHERE=PDC $END
$PDC PTSEL=CONNOLLY CONSTR=CHARGE $END
$FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END
$ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,2,1,5,1,1,6,5,1,7,5,1,8,2,1,9,4,1,10,9,
1,11,8,1,12,11,1,13,8,1,14,13,1,15,14,1,16,14,1,17,13,1,18,17,1,19,17,
1,20,14,1,21,16,1,22,21,1,23,20,1,24,23,1,25,24,1,26,25,1,27,26,1,28,26,
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1,29,26,1,30,29,1,31,29,1,32,29,1,33,32,1,34,33,1,35,33,1,36,33,1,37,20,
2,3,2,1,2,4,2,1,2,5,1,2,2,6,5,1,2,7,5,1,2,8,2,1,2,9,4,2,2,10,9,4,2,11,8,2,
2,12,11,8,2,13,8,2,2,14,13,8,2,15,14,13,2,16,14,13,2,17,13,8,2,18,17,13,
2,19,17,13,2,20,14,13,2,21,16,14,2,22,21,16,2,23,20,14,2,24,23,20,2,25,24,23,
2,26,25,24,2,27,26,25,2,28,26,25,2,29,26,25,2,30,29,26,2,31,29,26,2,32,29,26,
2,33,32,29,2,34,33,32,2,35,33,32,2,36,33,32,2,37,20,14,3,4,2,1,3,3,5,1,2,3,3,6,5,1,2,3,7,5,1,2,3,8,
2,1,3,3,9,4,2,1,3,10,9,4,2,3,11,8,2,1,3,12,11,8,2,3,13,8,2,1,3,14,13,8,2,3,15,14,13,8,3,16,14,13,8,
3,17,13,8,2,3,18,17,13,8,3,19,17,13,8,3,20,14,13,8,3,21,16,14,13,3,22,21,16,14,3,23,20,14,13,3,2
4,23,20,14,3,25,24,23,20,3,26,25,24,23,3,27,26,25,24,3,28,26,25,24,3,29,26,25,24,3,30,29,26,25,
3,31,29,26,25,3,32,29,26,25,3,33,32,29,26,3,34,33,32,29,3,35,33,32,29,3,36,33,32,29,3,37,20,14,
13,
$END
$DATA
File 15. Hessian Calculation for ascorbic acid for NAMD parameterization (truncated)
$CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=0 MULT=1 COORD=ZMT
NZVAR=54 $END
$CONTRL MAXIT=75 $END
$SYSTEM TIMLIM=999999999 MWORDS=235 $END
$SCF DIRSCF=.TRUE. $END
$STATPT NSTEP=1000 $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$ELPOT IEPOT=1 WHERE=PDC $END
$PDC PTSEL=CONNOLLY CONSTR=CHARGE $END
$FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END
$ZMAT IZMAT(1)=1,2,1,1,3,2,1,4,3,1,5,4,1,6,2,1,7,4,1,8,7,1,9,5,1,10,1,
1,11,7,1,12,11,1,13,4,1,14,7,1,15,11,1,16,11,1,17,12,1,18,8,1,19,10,1,20,9,2,3,2,1,2,4,3,2,2,5,4,3,
2,6,2,3,2,7,4,3,2,8,7,4,2,9,5,4,2,10,1,2,2,11,7,4,2,12,11,7,2,13,4,3,2,14,7,4,2,15,11,7,2,16,11,7,2,
17,12,11,2,18,8,7,2,19,10,1,2,20,7,5,3,4,3,2,1,3,5,4,3,2,3,6,2,3,4,3,7,4,3,2,3,8,7,4,3,3,9,5,4,3,3,10
,1,2,3,3,11,7,4,3,3,12,11,7,4,3,13,4,3,2,3,14,7,4,3,3,15,11,7,4,3,16,11,7,4,3,17,12,11,7,3,18,8,7,4,
3,19,10,1,2,3,20,9,5,4,
$END
$ZMAT DLC=.TRUE. AUTO=.TRUE. $END
$DATA
ascorbate toppar
File 16. Hessian Calculation for mimosine for NAMD parameterization (truncated)
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$CONTRL SCFTYP=RHF RUNTYP=HESSIAN ICHARG=-1 MULT=1 COORD=ZMT
NZVAR=63 $END
$CONTRL MAXIT=75 $END
$SYSTEM TIMLIM=999999999 MWORDS=235 $END
$SCF DIRSCF=.TRUE. $END
$STATPT NSTEP=1000 $END
$BASIS GBASIS=N31 NGAUSS=6 $END
$ELPOT IEPOT=1 WHERE=PDC $END
$PDC PTSEL=CONNOLLY CONSTR=CHARGE $END
$DATA
mimosine toppar
$FORCE PURIFY=.TRUE. PRTIFC=.TRUE. DECOMP=.TRUE. $END
$IZMAT IZMAT(1)=2,1,3,2,4,3,5,4,6,5,7,2,8,4,9,8,10,9,11,1,12,9,13,12,14,12,
15,3,16,5,17,6,18,7,19,8,20,8,21,9,22,10,23,10,3,2,1,4,3,2,5,4,3,6,5
,4,7,2,3,8,4,3,9,8,4,10,9,8,11,1,2,12,9,8,13,12,9,14,12,9,15,3,2,16,5,4,17,6,5,18,7,2,19,8,4,20,8,4,
21,9,8,22,10,9,23,10,9,4,3,2,1,5,4,3,2,6,5,4,3,7,2,3,4,8,4,3,2,9,8,4,3,10,9,8,4,11,1,2,3,12,9,8,4,13,
12,9,8,14,12,9,8,15,3,2,1,16,5,4,3,17,6,5,4,18,7,2,3,19,8,4,3,20,8,4,3,21,9,8,4,22,10,9,8,23,10,9,8
,
$END
Appendix C
NAMD Configuration Files
File 17. General configuration file for the rapid equilibration of proteins
# Equilibration run
#
# Monday May 26th, 2008
#
# Edward W. Lowe Jr
# Merkler Research Group
# Department of Chemistry
# University of South Florida
structure
coordinates
seed 238897325
binaryoutput

dbm_for_equil.solvated.ionized.psf
dbm_for_equil.solvated.ionized.pdb
on
168

outputname
DCDfile
# output frequency
outputenergies
outputtiming
restartfreq
DCDfreq

dbm_equilibration
dbm_equilibration.dcd

1000
1000
10000
1000

# integration parameters
timestep
rigidBonds
nonbondedFreq
fullElectFrequency 1
stepspercycle
10
# FF
paraTypeCharmm
parameters
parameters
exclude
1-4scaling
switching
cutoff
switchdist
pairlistdist
# PBC
cellBasisVector1
cellBasisVector2
cellBasisVector3
cellOrigin
wrapall
# PME
PME
PMEGridSizeX
PMEGridSizeY
PMEGridSizeZ

1.0
all
1

on
par_all22_prot+Cu+ASC+MIM.inp
par_all27_prot_lipid_na.inp
scaled1-4
1.0
on
12.0
10.0
14.0

94.0
0.0
0.0
0.0
on

0.0
94.0
0.0
0.0

0.0
0.0
94.0
0.0

on
96
96
96
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# set temperature to 0 initially
temperature
0
# fix the backbone atoms and coppers in DBM
fixedAtoms
on
fixedAtomsForces
on
fixedAtomsFile
dbm_for_equil.solvated.ionized.fixed.pdb
fixedAtomsCol
B
# turn on constraints for all of the alpha carbons in DBM
constraints
on
consRef
dbm_for_equil.solvated.ionized.constrained.pdb
consKFile
dbm_for_equil.solvated.ionized.constrained.pdb
consKCol
B
# set piston will large damping
langevin
on
langevinDamping
5
langevinTemp
310.15
langevinHydrogen
off
langevinPiston
on
langevinPistonTarget 1.01325
langevinPistonPeriod 100
langevinPistonDecay 50
langevinPistonTemp 310.15
useGroupPressure
yes
# run one step to get into scripting mode
minimize
0
# turn off langevin pressure control dynamics
langevinPiston
off
# minimize non-backbone atoms
minimize
10000
# minimize all atoms
fixedAtoms

off
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minimize
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10000

# heat with alpha carbons constrained
run
10000
# equilibrate volume with alpha carbons constrained (NPT on)
langevinPiston
on
run
10000
# equilibrate volume without constraints (1ns NPT)
constraintScaling
0
run
1000000

File 18. General configuration file for long molecular dynamics simulations using multiple
stepping algorithm
#
# PHM domain with bound coppers
# NPT 80 ns run for asc binding site
# Saturday July 20th, 2007
#
# Edward W. Lowe Jr
# Merkler Research Group
# Department of Chemistry
# University of South Florida
structure
coordinates
bincoordinates
extendedsystem
binvelocities

PHM+ox_asc_solvated_ionized.psf
PHM+ox_asc_solvated_ionized.pdb
PHM+ox_asc_NPT_WRAPALL_17.restart.coor
PHM+ox_asc_NPT_WRAPALL_17.restart.xsc
PHM+ox_asc_NPT_WRAPALL_17.restart.vel

seed 238897325
binaryoutput
outputname
dcdfile

on
PHM+ox_asc_NPT_WRAPALL_18
PHM+ox_asc_NPT_WRAPALL_18.dcd
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# output frequency
outputenergies
outputtiming
restartfreq
DCDfreq

10000
10000
10000
10000

# integration parameters
timestep
rigidBonds
nonbondedFreq
fullElectFrequency 4
stepspercycle
20
# FF
paraTypeCharmm
parameters
parameters
exclude
1-4scaling
switching
cutoff
switchdist
pairlistdist
# PBC
cellBasisVector1
cellBasisVector2
cellBasisVector3
cellOrigin
wrapall
# PME
PME
PMEGridSizeX
PMEGridSizeY
PMEGridSizeZ

1.0
all
2

on
par_all22_prot+Cu+ASC.inp
par_all27_prot_lipid_na.inp
scaled1-4
1.0
on
12.0
10.0
14.0

120.0 0.0
0.0
0.0 120.0 0.0
0.0
0.0 120.0
0.0
0.0
0.0
on

on
122
122
122

# set piston will large damping
172

langevin
langevinDamping
langevinTemp
langevinHydrogen
langevinPiston
langevinPistonTarget
langevinPistonPeriod
langevinPistonDecay
langevinPistonTemp
useGroupPressure
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on
5
310.15
off
on
1.01325
100
50
310.15
yes

# run one step to get into scripting mode
minimize 0
# MD for 80 ns
run 80000000
File 19. General configuration file for steered molecular dynamics simulations
# Edward W. Lowe Jr
# Merkler Research Group
# Department of Chemistry
# University of South Florida
#
# Constant Velocity Pulling of reductant from PHM
structure
PHM+ox_asc1_bound_solvated_ionized.psf
coordinates
PHM+ox_asc1_bound_solvated_ionized.pdb
bincoordinates
1.coor
outputName
asc_pulling_1_022408
set temperature
310
firsttimestep
0
# Input
paraTypeCharmm
parameters
parameters
temperature
wrapWater

on
par_all22_prot+Cu+ASC+MIM7.inp
par_all27_prot_lipid_na.inp
$temperature
on
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wrapAll
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on

# Force-Field Parameters
exclude
scaled1-4
1-4scaling
1.0
cutoff
12.
switching
on
switchdist
10.
pairlistdist
14.
# Integrator Parameters
timestep
1.0 ;# 1fs/step
nonbondedFreq
1
fullElectFrequency 1
stepspercycle
10
# Constant Temperature Control
langevin
off
langevinDamping
5
langevinTemp
$temperature
langevinHydrogen
no
restartfreq
500
dcdfreq
500
xstFreq
500
outputEnergies
100
outputPressure
100
# Fixed Atoms Constraint
if {1} {
fixedAtoms
on
fixedAtomsFile
PHM+ox_asc1.SMD.ref
fixedAtomsCol
B
}

SMD
SMDFile
SMDk
SMDVel

on
PHM+ox_asc1.SMD.ref
7
0.0001
174

SMDDir -0.467180057326 -0.0811620777483 0.880429163064
SMDOutputFreq
10
run

1000000
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Appendix D
Monooxygenase X: Homology modeling results

List of Figures
(Figure )

Figure A.1. Monooxygenase X solvated and ionized prior to equilibration using NAMD.
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(Figure )

Figure A.2. Monooxygenase X in ribbon representation of the secondary structure after
equilibration with NAMD.
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(Figure)

Figure A.3. The rmsd versus time graph for the equilibration of Monooxygenase X using
NAMD. Rmsd = 1.86.
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Appendix E
Equilibration results of oxidized PHM
(Figure )

Figure A.4. PHM crystal structure in ribbon format solvated prior to equilibration with
NAMD.
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(Figure)
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Figure A.5. The time versus rmsd for the equilibration of oxidized PHM with NAMD. Rmsd =
2.057
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Appendix F
Dopamine β-Monooxygenase: Homology model
(Figure )

Figure A.6. Dopamine β-monooxygenase homology model prior to refinement with NAMD.
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(Figure )

2.5

Rmsd, Anstroms

2

1.5

1

0.5

0
0

200

400

600

800

1000

Time, picoseconds
Figure A.7. The rmsd versus time for the equilibration of dopamine β-monooxygenase
homology model. Rmsd = 1.86
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Appendix G

Synthesis of 14C-mimosine

(Figure )
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Figure A.8. Mimosine synthase reaction scheme.
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(Figure )

Figure A.9. The synthetic scheme for O-acetyl-serine
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(Figure )

Figure A.10. The scheme of the synthesis of dihydroxypyridine.
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(Figure )
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Figure A.11. The chromatogram of the separation of a mimosine standard solution by RPHPLC.
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Figure A.12. The chromatogram of the RP-HPLC separation of dihydroxypyridine.
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(Figure )
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Figure A.13. The scheme of the enzymatic synthesis of 14C radiolabeled mimosine. Note
that * = 14C

188

Appendices

(Figure )
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Figure A.14. The chromatogram of the RP-HPLC separation of a 30-minute time point for
the conversion of O-acetylserine and 3,4-dihydroxypyridine to mimosine by mimosine
synthase.
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